James Voos, MD, chair of the Department of Orthopedics and Sports Medicine at University Hospitals Cleveland Medical Center, Cleveland Browns team physician, and president of the NFL Physicians Society (NFLPS), shares his goals for the society and offers insight into how he is using biotechnology to monitor recovery, prevent further injuries, and safely return athletes to competition.

James Voos, MD, president of the NFL Physicians Society (NFLPS), discusses the society's efforts to standardize care for NFL players across the league in an interview with SmartTRAK at the American Orthopaedic Society for Sports Medicine (AOSSM) 2025 Annual Meeting recently held in Nashville, TN.

Dr. Voos also shares an update on ongoing clinical research for osteoarthritis treatment with stem cells. To listen to the interview, please click on the following video (4:18 minutes). A link to download a complete transcript of the interview is alsoprovided below. 

SmartTRAK: Hi, this is Dave Shepard. I'm here at the AOSSM 2025. Keep watching for my interview with Dr. James Voos, who is the team physician for the Cleveland Browns, and also the president of the NFL Physicians’ Society. Dr. Voos, thanks for joining us.

James Voos, MD: Thank you very much for the invitation. I appreciate it.

Excellent. Tell me a little bit about the NFL PS and a little bit about what you're doing, what your initiatives are, what your goals are.

JV: As president of the NFL Physician Society, we represent all of the physicians that provide care for our professional athletes in football. That's not only our orthopedic surgeons, but our medical physicians and all of our associated consultants. So we help to provide standards for how to practice across the league, and that way we assure that every athlete and every team has ...

Interested in how biotechnology can be used to monitor recovery, prevent further injuries and safely return athletes to competition? Click
the button below to download the full transcript of SmartTRAK GM/Sr Analyst David Shepard's interview of James Voos, MD, president of the NFL Physicians Society (NFLPS) from AOSSM 2025.

Stewart Strong, Q’Apel Medical’s recently appointed CEO, discusses the company, his priorities and plans for growth in an interview with SmartTRAK at SNIS 2025 in Nashville, TN.

Stewart Strong, Q’Apel Medical’s recently appointed CEO, discusses the company, his priorities and plans for growth in an interview with SmartTRAK at the Society of Neurointerventional Surgery (SNIS) Annual Meeting held in Nashville, TN July 14-18, 2025. 

Strong says with recent challenges behind them, it’s the perfect time for him to join Q’Apel Medical. Given Q’Apel’s leadership position in balloon guide catheters, the full market launch of Zebra and the company’s pipeline leveraging its innovative laser-cut technology, he sees significant opportunity in the years ahead. To find out more, listen to the following video (21:12 min). A transcript of the interview is also provided below. 

SmartTRAK: Hi, everyone. Anne Staylor here with SmartTRAK. Today, I'm at the Society of Neurointerventional Surgery meeting in Nashville, and I have the pleasure of talking with Stewart Strong, the new president and CEO of Q'Apel Medical. Stewart, thanks for talking with me today.

Stewart Strong: Thanks, Anne. Great to be here.

So you are really new to the company. They just announced July 1st that you were in this new role. So I think a lot of people, myself included, want to hear a little bit about you. So do you want to start by just talking about yourself?

SS: Sure. And you're right, four weeks into the role, but I've been really excited about not only the opportunity here at Q'Apel, but also with the space that we're in and the growth of the neurovascular space. So to give you a little bit of background on me, I've been in the medical device industry for over 25 years. I've spent time in spaces like interventional cardiology, electrophysiology, and have really focused on areas where we can drive growth. That's one of the things I really enjoy is joining a company where we can drive exponential above-market growth and continue to add value to customers and to stakeholders through that growth.

I knew you're really experienced from what I had heard. So as you enter this new company, what are your priorities?

SS: I think what I saw in doing my own due diligence on Q'Apel is a company that has terrific innovation. When you think about innovation, you think about quality, you think about Q'Apel, and that's been validated here. I have had a chance to speak with a number of physicians that use our products. Everybody really looks at us as ...

Curious about where Q’Apel Medical is headed next? We sat down with CEO Stewart Strong for an exclusive interview conducted by Anne Staylor, SmartTRAK’s Executive Editor and VP & GM of Neuro Therapies. Click below to download the full transcript and get an inside look at Q’Apel’s future plans, innovations and strategic goals.

In this comprehensive article, SmartTRAK provides an overview of the WISeR Model and its potential market impact on skin substitutes.

Click the button below to download and read the complete article "Skin Substitutes Get WISeR – Will it Impact the Market?" by Jay Merkel, SmartTRAK Sr Analyst, Wound.

SmartTRAK is excited to attend the Society of Neurointerventional Surgery’s (SNIS) 22nd Annual Meeting & Fellows Course in Nashville, Tennessee, from July 14-18, 2025. Anne Staylor, VP/GM of Neuro Therapies, will cover the latest news at the conference and provide updates on key studies, trends, and technologies affecting the market for ischemic and hemorrhagic stroke devices. 

Meanwhile, click the image below to watch Anne’s video update on the US Market for Mechanical Thrombectomy in 2025.

Spinal Simplicity’s Chief Strategy Officer Neil P. Dougherty shares how the company is advancing minimally invasive solutions to enhance patient outcomes.

Neil P. Dougherty, chief strategy officer of Spinal Simplicity, discusses the company’s position in the interventional spine and pain market, what the company looks forward to in the future and how it serves patients treated by spine surgeons and interventional pain management physicians.

Click on the following video (17:18 min) to learn more. A link to download a complete transcript of the interview is also provided below.

SmartTRAK: Hi, this is Erin Dorgan with SmartTRAK. I'm here today with Neil Dougherty, chief strategy officer with Spinal Simplicity. Thanks for joining me today, Neil.

Neil P Dougherty: Glad to be here. Thanks, Erin.

You're welcome. Can you share a little bit more about what you do at Spinal Simplicity? I know, based upon your background, you've been in the interventional space for a while. How did you end up here at Spinal Simplicity?

NPD: Well, in a startup you wear a lot of hats. So I came to Spinal Simplicity first as a vice president of sales and then moved over to focus on just business development and more of an offensive role for our expansion. And as the company grew, an opportunity for promotion was there to get to my now title, chief strategy officer.

I have been in the interventional pain space for a long time. Gosh, it's about 15 years now. Started with Medtronic, doing spinal cord stimulators and intrathecal pumps--just over five years there. Then went over to Vertiflex in that startup campaign bought by Boston Scientific and only a year of integration there after that purchase.

And then how could you forget? When the whole world basically shut down during COVID, I was kind of losing my mind a little bit. I had a couple phone calls from some doctors and also Todd Moseley, the CEO of Spinal Simplicity, and founder. And I started learning more about Spinal Simplicity. I saw their main product, Minuteman. I was like, ‘This is where I need to be.’

Okay. So speaking of Minuteman, and obviously with your background, Boston Scientific recently discontinued Vertiflex Superion. Do you think that is an opportunity for Spinal Simplicity and Minuteman to explore those customers? Or how would you describe that?

NPD: I think so. I'd like to describe it as just an acceleration to where most of those customers were probably going to graduate anyway. Superion was a great idea. I mean, it wasn't even a Vertiflex idea. This is, indirect decompression has been a great studied spine idea for a long time and it certainly wasn't the first ISP out there, but the aim is ...

Click the button below to download and read the complete transcript of SmartTRAK's interview with Neil P. Dougherty, CSO of Spinal Simplicity conducted by Erin Dorgan, SmartTRAK Sr Analyst, Spine & Bone Replacement.

SmartTRAK provides insights into the latest trends, research and consensus opinions in surgical Orthobiologic treatments and non-operative regenerative medicine from this year’s BA Summit and AANA meetings.

Nearly half a billion in US dollars has been invested in Advanced Wound Care over the last 18 months. Learn where the money is going.

Over the past three years the global Advanced Wound Care Market has almost doubled, an exciting market for investment according to SmartTRAK estimates. The biggest deal in Advanced Wound Care (AWC) has been Coloplast's acquisition of Kerecis in 2023. Kerecis, a startup in the US Skin Substitute Market, demonstrated strong growth and the potential to have a global presence, justifying the high price. Startups have been a key component of the market, with new technologies and products over the years, and have been advancing their portfolios through IPOs, strategic partnerships, and investments. 

This downloadable article reviews the recent top deals and investment trends in AWC, including:

• Recent Global Wound Care Investments
  • Top Deals and Investments Jan 2024 through June 2025
• Market Trends
  • Although the US Skin Substitute/ CAMPs Market has seen exponential growth in the last few years, that isn't where global investment is occurring.
• Investment by Geography
  • US and Canada Wound Care Investments
  • UK, Europe, and Rest of World (ROW)
• Early-Stage Investments
  • Non-Dilutive Funding Sources
  • Strategic and Insurance Provider Investments

Want to know which deals are shaping the future of wound care? Click below to download the full article, “Deals in Advanced Wound Care,” co-authored by Dr. Mitchell C. Sanders, CEO, ProDevLabs and Susan Paquette, SmartTRAK Senior Advisor, Wound, to get a firsthand look at the key investment trends driving this dynamic market.

SmartTRAK, the leading provider of actionable market intelligence for orthopedic companies, and Foot Innovate, the premier platform for Foot & Ankle (F&A) surgeon education and clinical insights, are excited to announce a strategic co-marketing partnership. This collaboration brings together two industry leaders to launch a cutting-edge F&A market research solution that fuses robust analytics with real-world surgeon experience.

The joint offering blends SmartTRAK’s trusted data expertise with Foot Innovate’s deep network of engaged surgeons to deliver a

Dr Cheryl Blanchard, president and CEO of Anika Therapeutics, discusses the company, technology and developments for future growth in an interview with SmartTRAK.

In a recent interview with SmartTRAK, Dr. Cheryl Blanchard, president and CEO of Anika Therapeutics, discussed the company’s strategic direction, proprietary technology and advancements in its next-generation osteoarthritis (OA) pain management and regenerative solutions.

To find out more about the company, its differentiated technologies, products and growth strategy, click on the following video (26:40 min).

Interview topics by timecode are provided below, as is a link to download a complete transcript of the interview.

Interview Outline by Timecode:

00:20 Introduction to Anika Therapeutics, president and CEO Dr. Cheryl Blanchard and the company’s strategy.
01:14 The US OA Injectables Market and Anika’s next-generation OA pain solution, Cingal.
02:52 Cingal’s advantages and how it fit in the treatment continuum.
04:56 Cingal’s positioning and clinical trials’ progress.
10:47 Marketing communication, commercial and pricing approach and beyond knee OA.
13:42 Hyalofast, Anika’s next-generation cartilage repair solution.
17:25 Anika’s regenerative platform and the Integrity Implant System.
19:54 Cheryl Blanchard’s take on the next major disruptive force.
22:42 Thoughts around healthcare policy changes, tariffs uncertainty and other macro trends.

Click the button below to download and read the complete transcript of SmartTRAK's interview with Dr. Cheryl Blanchard, president and CEO of Anika Therapeutics, conducted by  Freddy Buntoum, SmartTRAK Senior Analyst, Orthobiologics and Regenerative Medicine.

Nitric Oxide (NO) has numerous benefits for wound healing but has challenges associated with its delivery. Several companies are addressing those challenges and creating an exciting opportunity in wound care.

Nitric oxide (NO) was named “Molecule of the Year” by the journal Science in 1992, and six years later, three US scientists were awarded the Nobel Prize for Physiology and Medicine for their efforts to prove that NO, an endogenous gas and free radical, could have crucial biological effects. One of the well-known medical uses of NO is via nitroglycerin, a precursor to NO, to prevent and treat chest pain (angina). It works by relaxing blood vessels, which decreases the amount of work the heart has to do. NO has been identified for its value in chronic wound healing for many years because of its function in vasodilation, relaxing blood vessels and increasing blood flow, as well as its broad-spectrum antimicrobial and antibiofilm activity.

No products have yet reached the market for chronic wounds; however, SmartTRAK has noted increasing activity related to the benefits of NO for wound healing. In fact, an article was published earlier this year entitled “Emerging Strategies for Nitric Oxide Production and Their Topical Application as Nano Dressings to Promote Diabetic Wound Healing.” The article identified four primary modes in which NO benefits the diabetic wound healing process: providing antimicrobial properties, promoting angiogenesis, regulating inflammation and promoting tissue regeneration and remodeling.

This market outlook article will discuss in detail the following subjects:

Thomas Lash, COO and co-founder of Aatru Medical, talks about the company’s innovative single-use negative pressure device, NP-Sims, a Negative Pressure Surgical Incision Management System.

Thomas Lash, chief operating officer and co-founder of Aatru Medical elaborates on the company’s strategy to mitigate the risk of surgical site infections through NP-SIMS, their single-use negative pressure surgical incision management system. To listen to the interview, please click on the following video (21:21 minutes). A link to download a complete transcript of the interview is provided below. 

SmartTRAK: Hi, this is David Shepard, senior analyst with SmartTRAK. Today it's my pleasure to be joined by Tom Lash, COO and co-founder of Aatru. He's going to talk to us today about a product that he co-invented, called NPSims. Tom, tell us a little about your company and about the product.

Tom Lash: We started the business about eight years ago, a small research and commercialization team with the goal of developing an alternative solution for the single-use, disposable negative pressure wound therapy market.  Kind of a mouthful to say that, but in essence, what we were trying to do is looking at the predicate devices that are on the market, we knew that if we were going to try and have a product that could make an impact on that market segment, it would be necessary for us to find an innovative mode of action to create the negative pressure without the current use of electromechanical pump which powers the leading products that are in use today. They have an electromechanical pump. They're battery-operated. They have software. Those products were primarily devised for the open or chronic wound market, and because of our focus on the surgical incision market, we were able to design something that was different. We believe the current products are probably over-engineered for the surgical incision market. So, our approach was to devise ...

Click the button below to download and read the complete transcript of SmartTRAK's interview with  Aatru Medical's Co-Founder and COO Thomas Lash, conducted by  David Shepard, SmartTRAK Lead Analyst, Orthobio & Regen.

Alyssa Huffman, CEO of Allumin8, discussed the company and its efforts to create a new product category of therapeutic hardware in an interview with SmartTRAK on May 9, 2025, at the 2025 North American Spine Society (NASS) Biologics Interventions meeting in Chicago, Illinois. The company is focused on treating over 200 unique bone disorders and diseases, and its first product is focused on the Spinal Hardware Market.

Click on the following video (8:49 min) to learn more. A link to download a complete transcript of the interview is also provided below.

SmartTRAK: Hi, this is Erin Dorgan, senior analyst here at SmartTRAK. I'm here today with Alyssa Huffman, CEO of ALLUMIN8. Alyssa, thank you for joining me today. Can you share a little bit more about your background and your role at ALLUMIN8?

Alyssa Huffman: Absolutely, Erin. Thanks for being here. I started in the clinic, then worked in the OR, went into sales, distribution. I worked my way into an executive function and then decided I was going to bet on myself. I have 30 years of experience throughout orthopedic spine biologics regenerative therapies.

That's awesome.

AH: And computer navigation.

Well, that's quite extensive. So we're here today at the NASS Biologic Interventions for Spinal Pathologies meeting. Why are you here with ALLUMIN8? What's the purpose for ALLUMIN8 presenting?

AH: Dr. Zorica Buser, she asked me to come and talk to the researchers and physicians about how to design a product that will actually commercialize and can get funded. There's a very different issue that's going on right now where products that only are a little bit, 1% to 3%, better than what's currently available on the market. There's a plethora of those, and so we have ...

Click the button below to download the complete transcript of our interview with Allumin8 CEO Alyssa Huffman, conducted by Erin Dorgan, SmartTRAK Senior Analyst.

SmartTRAK spotlights CytexOrtho, the AAOS 2024 OrthoPitch winner, as it develops its biodegradable implant to address early joint degeneration. 

In this interview with SmartTRAK, CytexOrtho CEO Brad Estes, PhD, discusses the company’s cartilage repair implant, ReNewHip, an engineered bicomponent implant used for cartilage regeneration.

To find out more about CytexOrtho and its technology, click the image below to watch the video (26:37 min). A link to download a transcript of the interview is also provided below.

SmartTRAK: Hi, this is Emily Meng with SmartTrak. Today I'm here with CytexOrtho CEO Brad Estes. Thanks, Brad, for joining me today.

Bradley Estes: Yeah, I'm happy to be here. Thanks for having me.

So, we'll just jump in and start asking you some questions. Let’s start with can you tell me about yourself and your background and how you got started with CytexOrtho.

BE: Yeah, it was kind of a circuitous route to get here. I started my career in the Medtech industry with Sofamor Danek, which was eventually acquired by Medtronic, and kind of did a lot of R&D in the heyday of spine, I like to say it, and was even on the team that did BMP-2. So that was a lot of fun seeing the role of a biologic in orthopedics and what that could really do to change the way patients are treated. And so I spent about eight years in Medtronic and then I left industry, came to academia, did a PhD at Duke and kind of retooled and learned the molecular biology, the stem cell biology, the tissue engineering and just kind of gained a whole new skill set. I got to work with some really great people and that kind of set us off on our journey of where we are today and kind of tie in some product development experience with science and having the right time and the right people and the right funding to push forward with CytexOrtho. And I'm sure I caused more questions in that response than answered, but I'm happy to fill in the gaps, too.

Can you tell us a little bit about CytexOrtho and what you guys are doing, and specifically, I guess, for ReNew Hip, since that's your product that is under development.

BE: So, our goal from the beginning has been to treat that patient that currently has no solutions. I'm talking the patient in their 30s, 40s or 50s that have early-stage hip disease, but they have no solutions right now. Their plight is kind of sad if you think about it. They go see their doctor, they have some hip pain, they're starting to not be able to do the things they want to do. And so, they take some ibuprofen, do some PT, and let's come back and see me in a year and that progresses for about seven or eight years typically. That's what our data tells us. That patient is just living with more chronic pain and increasing disability over that eight years until finally they can't take it anymore and then they replace their hip. And so, our technology is ...

Click the button below to download the complete transcript of our interview with Brad Estes, CEO of CytexOrtho, conducted by  SmartTRAK analyst Emily Meng.

SmartTRAK spotlights SentryX, a clinical-stage biopharmaceutical company developing a non-opioid platform for the treatment of acute pain after surgery,​ in an interview at AAOS 2025 in San Diego. 

SentryX Co-Founder and Chief Medical Officer Jorrit-Jan (JJ) Verlaan, MD, discusses the company’s novel implantable anesthetic for spine surgery applications in an interview with SmartTRAK at the American Academy of Orthopaedic Surgeons (AAOS) 2025 Annual meeting in San Diego. The hydrogel works with all types of small-molecule drugs with a release profile that can be tailored to specific clinical needs and surgical procedures.

To find out more about SentryX and its novel technology, listen to the following video. (13:37 min.) A link to download a transcript of the interview is also provided below.

Hi, I’m Kristine Jacques, a Senior Analyst with SmartTRAK Spine. We are here at the American Academy of Orthopedic Surgeons 2025. I’m sitting down with Dr. JJ Verlaan, a spine surgeon, co-founder, and Chief Medical Officer for SentryX, a Netherlands-based company developing a groundbreaking non-opioid solution for postoperative pain. First of all, Dr. Verlaan, I want to congratulate you on being one of the top four finalists inthe OrthoPitch Event at the Academy this year. It’s quite an honor.

Dr. Jorrit-Jan Verlaan: Thank you very much.

Thank you so much for sitting down with the SmartTRAK team. I’d like to start out with you telling us about your background and how the idea came about for the Hydrogel and starting SentryX.

JJV: Thank you so much. I'm a surgeon from Utrecht in the Netherlands. I've been practicing spine surgery from the moment I got board-certified. Rapidly, during work in my practice, I noticed that patients after spine surgery are all in a lot of pain. The moment that you realize that, and you actually ask the patients how much pain they have, on a scale of 0-10 they sometimes respond with a 12. I had a chat with an anesthesiologist one day in between surgeries. We were discussing what is out there right now to treat pain. The anesthesiologist, she told me, "Well, not much, really. We're still relying on opioids. Maybe we could do something with local anesthetics, but it's not working long enough at this point." That kind of sparked the idea of doing something locally to treat the pain, but differently. Soon after, I hit upon the idea that we're developing right now in the company.

How far along are you in the development?

JJV: We started in 2017, together with my partner Bas Oosterman who is the CEO of the company. First it was just a raw idea. We soon found out that this idea, it had never been done before. That gave us the opportunity to actually file IP on our solution and go for it. At the end of 2017  we officially founded the company. We got our first employees and collaborated with a renowned institute on biofabrication. We developed a new ...

Click the button below to download and read the complete transcript of SmartTRAK's interview with SentryX Co-Founder and CMO Jorrit-Jan (JJ) Verlaan, MD, conducted by Kris Jacques, SmartTRAK Sr Analyst.

Wound GM Kris Flinn and Senior Analysts Elizabeth Anderson and Jay Merkel discuss the impact of delay and how industry players may choose to react.

On April 11, 2025, Centers for Medicare and Medicaid Services announced that the Treatment of Diabetic Foot Ulcers and Venous Leg Ulcers Final Local Coverage Determinations (LCDs) effective date will be delayed until January 1, 2026. In this video (16:43 minutes), SmartTRAK Wound GM Kris Flinn and Senior Analysts Elizabeth Anderson and Jay Merkel discuss the impact of delay, and how industry players may choose to react.

The SmartTRAK Wound Team will be in attendance at the upcoming SAWC Spring conference in Grapevine, TX (April 30 to May 4). Please register here to meet the team.

Recently, SmartTRAK's VP of Sales, Joe Mish, sat down with the Alpha Sophia podcast to discuss the impacts of data on the Medtech market. Hosted by Alpha Sophia founder & CEO Paul-Lukas Hoffschmidt, the podcast dives deep into the cutting-edge of MedTech innovations and commercial trends.

In this video, Joe breaks down how SmartTRAK delivers critical market intelligence to MedTech companies, helping them track trends, product performance and market changes. He explores how the Alpha Sophia partnership enhances real-time intelligence, enabling businesses to quickly act on insights, stay ahead of industry shifts, adapt to changing market dynamics and maintain a competitive edge in an evolving market. Click the video below to watch the podcast.

SmartTRAK and Alpha Sophia together offers a data-driven, AI-powered solution for commercial teams in the healthcare sector. Click the button below to watch our webinar titled "Growth in 2025: More Than Targeting" outlining how SmartTRAK and Alpha Sophia can accelerate business opportunities by combining deep market insights with advanced targeting strategies, ultimately enabling sales teams to engage more effectively with the right customers at the right time. 

We are pleased to announce that David Shepard has joined the SmartTRAK team as Senior Analyst, Orthobiologics and Regenerative Medicine. Prior to joining SmartTRAK, for the last 22 years, David has worked for Arthrex as the Senior Director of Orthobiologics and Vet Systems, where he led global business development and product strategy across two diverse portfolios, driving innovation in regenerative medicine and orthobiologics. Before that, he was Director of Donor Services at the University of Florida Tissue Bank, where he oversaw tissue recovery operations and processor distribution for all donors across the UFTB region, confirming compliance, efficiency and optimized recovery rates.

Meet David Shepard:

What is your role with SmartTRAK? I am a senior analyst with the OrthoBio Team.

What do you like about SmartTRAK? I have been using SmartTRAK for years to keep up with the latest developments in the fast-moving Orthobiologics space. This unique environment covers many areas of medical practice, so staying on top of the latest news, emerging tech, research, and IP is critical to the success of any company. Now that I am on the other side, it’s like being a kid in a candy store.

What is something special or unique that you bring to SmartTRAK subscribers? I have worked in various roles in the Orthobiologics space, leading upstream product development from early research to product launch, downstream marketing, sales management, and evaluation of emerging technologies. I have also had the opportunity to work alongside and learn from some of the preeminent thought leaders in the field. This has prepared me to help companies reach their goals using the power of data analytics and experience in this diverse field.

What do you think the biggest promise of medical technology (in your area) is? With incredible materials, instruments, and implants now available to physicians, the one area that remains out of their control is the biology of their patients and how that will impact their final repair and long-term outcome. It is well-accepted that Orthobiologics (Cells, Signals, and Scaffolds) have the best opportunity to improve patient outcomes. While it is hard to pick a single area as the most promising, I would say that cellular and cell secretory factors may hold the most potent potential to direct regenerative repair and even early diagnosis.

What are your favorite online websites or resources that you check every day? For years, I have started my day reviewing the SmartTRAK updates and augmenting these overviews by cruising PubMed to dig into more of the details. Even some of the best research can miss fine details that hold the truth.

How do you keep your medical device research skills sharp? I read, read, read…and I have never been shy about contacting authors to get more details about the research I am reviewing. I enjoy talking to companies about their new technologies and clinicians who are early adopters so I can better understand the problems they are trying to solve and how their technique or product solves those problems. As my father has always told me, surround yourself with people who are better than you, and that is easy to do when working at SmartTRAK.

If you could have one superpower, what would it be? This is a fun question. I would have to say teleportation. I love to travel and hate traffic; this power would resolve that conflict.

What was the last show you binge-watched? Hmmm…tough one. I am more of a binge reader but almost anything in the sci-fi genre will fit the bill regarding series and watching. Separation has been and interesting one. Good characters that you care about are key.

What can we find you doing when you’re not working? You can often find me on the ice. I do my best to stay fit as I remain an avid hockey player, playing 3+ games weekly. All three of my boys also play, so it is a busy house. My wife and I also enjoy hiking in the mountains of NC.

If you'd like to learn more about SmartTRAK and how it can increase proficiency, improve productivity and reduce costs for your company, or if you would like to meet with David, just click the button below.

We are pleased to announce that Elizabeth Anderson has joined the team at SmartTRAK as Senior Analyst, Biologics. Before joining SmartTRAK, Elizabeth got her start at Healthpoint in Texas and has since worked in various roles with several of the top companies in the biological space, including Smith+Nephew and Organogenesis. 

Meet Elizabeth Anderson:

What is your role with SmartTRAK? My role with SmartTRAK will be as a Senior Analyst for the Biologics module.

What do you like about SmartTRAK? I have been using SmartTRAK since the platform started. My favorite feature is the ability to have information relevant to both the commercial and clinical sides of the market in one place. 

What is something special or unique you bring to SmartTRAK subscribers?
The majority of my roles have been responsible for market research and business intelligence. I have extensive experience combining primary and secondary data to get a full picture of the market.

What do you think the biggest promise of medical technology (in your area) is?  In the Biologics space, it isn't easy to choose just one. A lot of research is looking into the ability to impregnate matrices or grafts with growth factors or cell types that a patient may be missing based on their pathophysiology. 

How will it change everything? This would allow clinicians to tailor their tx specifically, giving the patient what is needed to heal. Of course, this hinges on the proper diagnostics, but I think it is where we are headed.

What are your favorite online websites or resources that you check every day? Of course, I stay up to date with SmartTrak and LinkedIn, my go-to sources, but I also monitor the CMS website in this space.

How do you keep your medical device research skills sharp? I keep my skills sharp by attending conferences, reading published clinical studies, and talking to clinicians on the front lines.

What was the last presentation you gave and to who, about what?  My last presentation was a forecast model for a new product launching clinical trials to enter the US market. It was for a US Business Development Director for an OUS manufacturer.

What was the last show you binge-watched? The last show I binge-watched was the limited series American Primeval on Netflix. It is a good story.

What is your life like outside of SmartTRAK? Outside of SmartTRAK, I run a lot, tend to my senior dog, and try to teach myself new baking skills. I have backed off a lot of the long-distance running but still do a few endurance events.

If you'd like to learn more about SmartTRAK and how it can increase proficiency, improve productivity and reduce costs for your company, or if you would like to meet with Elizabeth, just click the button below.

To find out more, watch the following video (4:27 min). A link to a transcript of the interview is also provided below. 

SmartTRAK: Hi, this is Sharon O'Reilly. I'm at the Canaccord Conference before the 2025 AAOS, and I ran into Alessandra Pavesio, who's so excited about her company, Doron Therapeutics.

So, Alessandra, why don't you tell us a little bit about the company and some of the exciting new developments.

Alessandra Pavesio: It's always great to see you, Sharon. I love bumping into you and having some really good news to deliver. First of all, what is Doron Therapeutics? It's a management-led spin-off. We really were passionate about a technology that we've developed with Bioventus, and when Bioventus divested from this program for financial considerations, we were able to negotiate a very favorable deal to actually set up a spin-off company and go raise private capital to invest in the program.

The good news is that, yes, we've set up a company. Yes, we have raised private capital. And so now we are really up and running and getting ready to start a Phase III study.

Big milestone that we've accomplished is that we've been recognized by FDA as an RMAT therapy. RMAT means Regenerative Medicine Advanced Therapy. As such, that means attention from senior officials at FDA that are really partnering with you to get this product to market for the patients that we serve. Super excited.

SmartTRAK: Tell us about the product.

AP: So our lead program is called MOTYS. It's placental-derived injectable therapeutic. It's a biological drug that ...

Click the button below to download and read the complete transcript of SmartTRAK's interview with Doron Therpeutics' CEO Alessandro Pavesio, conducted by Sharon O'Reilly, SmartTRAK Founder and CEO.

SmartTRAK will be attending AAOS 2025 this week. Join us at AAOS to explore our solution and discuss our roadmap for expanding into other orthopedic markets. Learn more about our Brand Tracker here or schedule time to Meet with Us at the show!

• Expanding Reimbursement for Lymphedema Products 
  • One of the biggest growth drivers for compression therapies in 2025 is expanding reimbursement for the treatment of lymphedema. With more than three million lymphedema patients estimated in the US alone, SmartTRAK expects ... (read more)
• Improving Ease of Use for Compression Garments
  • SmartTRAK expects several companies to develop or refine compression garments in the years ahead with a focus on improving ease of use. With the growing number of patients having access to compression garments day and night, it’s become even more important for ... (read more)
• Dynamic Compression Innovations Improving Portability
  
  • In the world of dynamic compression, portability is the name of the game and SmartTRAK expects to see ... (read more)

Want to stay ahead of the curve in the US compression device market for 2025 and beyond? Industry trends, regulatory changes and new reimbursement codes are shaping the future—are you prepared?

Click the button below to download Jay Merkel’s market outlook article, "Feel the Pressure: Compression Trends for 2025." As SmartTRAK’s senior analyst, Wound, Jay provides an informative analysis of the latest market shifts, including new compression codes and major code revisions set to take effect on April 1, 2025.

SmartTRAK’s new global procedure and brand share analytics tools for the hip and knee markets transform MedTech market intelligence with faster, smarter insights

SmartTRAK, the leading MedTech market intelligence platform in Orthopedics, Wound Care, Regenerative Medicine and Neuro Therapies, is revolutionizing strategic decision-making with the launch of new US and global procedure tools, brand share analytic, and price estimation tools. Designed to save time and reduce reliance on costly, complex datasets, these tools deliver unparalleled speed and depth of market insights for MedTech companies.

Empowering the Hip and Knee Markets with SmartTRAK’s Brand Tracker

Now available for the hip and knee markets, SmartTRAK’s Brand Tracker offers a powerful suite of analytics tools, including dynamic charts, growth analyses, and detailed breakdowns of product and company brand share. Updated quarterly, Brand Tracker highlights five years of trends covering product mix, average price, and market share by facility type. Upcoming expansions will include Interventional Spine and other orthopedic markets in the coming year.

Global Reach with OUS Procedure Tracker

For customers operating internationally, SmartTRAK introduces the OUS Procedure Tracker powered by Quomeda, featuring ...

•  Joint Replacement Procedures Continue Migrating to the ASC Setting
  
  • In 2023, SmartTRAK estimated that approximately 10% of all US hip and knee replacement procedures were performed in an ambulatory surgery center (ASC) setting. This trend shows no signs of slowing down. Based on recent procedure trends data, SmartTRAK projects ... (read more)
  • While procedure volumes at ASCs have risen, Medicare reimbursement rates continue to drop. SmartTRAK tracking of Medicare surgeon reimbursement shows ... (read more)
    
• Technology Trends: Streamlining, Personalization, Outcomes
  
  • Technology trends carrying over from 2024 include streamlining, personalization and outcomes. Some of the new products launching in 2025 are ... (read more)
• Potentially Disruptive Orthobiologic Therapies Coming to Market
  
  • New Orthobiologic injection therapies aim to better manage symptoms and modify disease progression in osteoarthritis (OA) patients. SmartTRAK feels this is ... (read more)
• Eight New Therapies on the Horizon That Could Impact Joint Replacement
  • Delaying surgeries by managing symptoms and  ... (read more)
  • Reducing the number of joint replacements performed: Advanced OA injectable therapies that more effectively target pain management could result in ... (read more)

Curious about the latest trends in the joint replacement market for 2025?    Click below to read her comprehensive market outlook article "Joint Replacement Trends to Watch in 2025" by Lisa Mahan, SmartTRAK's VP of Product Development & IT, Sr. Analyst Total Joints.

Carsten Schroeder, president and CEO of Terumo Neuro, discusses the company’s plans to capture share and become the market leader in neurovascular.

Carsten Schroeder, president and CEO of Terumo Neuro, discusses the company’s rebranding, plans for growth and becoming the market leader in neuroendovascular technologies in an interview with SmartTRAK. Listen to the video below to find out more, including how Terumo plans to innovate and take share via new disease states and markets in addition to its core neurovascular markets (ischemic, hemorrhagic and access).

Click on the video below to watch the interview (32:05 min). A link to download the complete transcript of the interview is available here. For more details, interview topics by timecode are provided below.

In 2024, SmartTRAK continued to empower you to Be The Expert in the MedTech industry. As your trusted resource for up-to-date industry insights, we delivered real-time market data, analysis and actionable insights across the orthopedics, wound care, regenerative medicine and neurotherapy markets. Here are SmartTRAK's Top Blog Posts from 2024, offering valuable perspectives from our expert analysts.

1. Skin Substitute Market Rocked by DOJ Investigations
   SmartTRAK believes the billions of dollars of Medicare abuse already uncovered is the tip of the iceberg in services billed to Medicare via the Physician Fee Schedule.
   
   
2. Medtronic: Making Waves At NANS 2024
   Medtronic executives discuss how the company is making waves in interventional pain, minimally invasive spine and deep brain stimulation in an interview with SmartTRAK at NANS 2024.
   
   
3. Spine Market Movers to Watch in 2024
   SmartTRAK highlights companies to watch as they continue their double-digit growth train with multiple catalysts for expansion in 2024.
   
   
   
   

On December 10, 2024, the Medicare Administrative Contractors (MACs) held a town hall session to discuss the Local Coverage Decisions (LCDs), “Skin Substitute Grafts/Cellular and Tissue-Based Products for the Treatment of Diabetic Foot Ulcers and Venous Leg Ulcers,” which were issued on November 14. The proposed LCDs were announced on April 25 of this year, a comment period followed, and then things went black as the MACs contemplated whether any changes should be made to the LCDs. Two key improvements in the final version included an increase in the number of skin substitute applications from four to eight and an increase in care time from 12 to 16 weeks. In this article, SmartTRAK will discuss the ongoing activities since these LCDs were announced, including the requirement for published peer-reviewed clinical evidence, market activities to shore up position and activities to rescind the LCDs. The article will close with SmartTRAK’s forward analysis of the impact of these LCDs on the market should they be implemented as planned.

Q’Apel Medical CEO Jodie Fam discusses the company, strategies for growth and Q’Apel’s approach to innovation in an interview with SmartTRAK at SVIN 2024. 

Q’Apel Medical CEO Jodie Fam discusses the company, its technologies, strategies for growth and Q’Apel’s approach to innovation in an interview with SmartTRAK at the Society of Vascular and Interventional Neurology (SVIN) held November 22-24, 2024 in San Diego, California. 

To find out more, click on the video below to listen to the interview (22:08 min). Click the button below to download a complete transcript of the interview.

In an interview with SmartTRAK, Gennaro Broya de Lucia, president of the National Board of Directors at PMI Sanità, offers a comprehensive summary of the challenges for the medical device market in Italy, which places hundreds of companies at risk in the country.

SmartTRAK’s suite of solutions for procedure and brand share analytics will provide orthopedics, wound care and neuro therapies companies with deeper market intelligence in one comprehensive platform

IRVINE, Calif.   SmartTRAK, the leading Medtech market and business intelligence solution in Orthopedics, Wound Care, Regenerative Medicine and Neuro Therapies, announces partnerships with STATinMED, LLC and Quomeda Ltd for the development of US and global procedure tools. A third partnership with a leading healthcare insights organization will enable SmartTRAK to offer customers a brand share and price estimation tool. These new tools, combined with SmartTRAK’s highly curated content and analyst-driven insights, reduces the need for expensive, complex data sets and increases the speed for strategic decision-making.

In an interview with SmartTRAK, Dr. Willi Schnorpfeil, an expert in reimbursement strategies, offers a comprehensive overview of the regulatory changes for advanced wound care products in Germany, which pose a potential threat to both market stability and patient care.

In an interview with SmartTRAK, Dr. Willi Schnorpfeil, managing partner of Value & Dossier and Reimbursement Specialist, provides insights into the scope, impact and potential future developments of changes in Germany’s reimbursement landscape, specifically concerning the Advanced Wound Dressing Market. Dr. Schnorpfeil highlights the challenges faced by the industry in meeting new evidence requirements and the possible implications for patient outcomes. This conversation sheds light on the complex regulatory environment in Germany and its broader implications for the healthcare sector across Europe.

Click on the video below to listen to SmartTRAK’s interview with Dr. Schnorpfeil (24:18 minutes), which was recorded on August 22. A link to download the complete transcript of the interview is also provided below. 

SmartTRAK is attending the upcoming North American Spine Society (NASS) meeting being held Sept. 25-28 in Chicago, Our team can't wait to see all of our colleagues at the premier meeting for the spine market. To help you get ready for the meeting, in the following video, Elise Wolf, SmartTRAK's VP & GM of Orthopedics and Digital, reviews the latest trends and developments in the Spine Enabling Technologies market.

If you would like to see more of what SmartTRAK has to offer in spine coverage, including some of our recent articles on the trends and developments in the Spine Enabling Technologies market, or if you would like to meet with us at NASS 2024 in Chicago,  just click the button below.

SmartTRAK is attending the upcoming North American Spine Society (NASS) meeting being held Sept. 25-28 in Chicago, and we can't wait to see all of our colleagues at the premier meeting for the spine market. To help you get ready for the meeting, Erin Dorgan, SmartTRAK Senior Analyst, Spine, has recorded this video update with an overview of the bone replacement products and companies to watch at NASS 2024.

If you would like to see more of what SmartTRAK has to offer in spine coverage and the bone replacement market, including some of our recent articles, or meet with us at NASS 2024,  just click the button below.

SmartTRAK is attending the upcoming North American Spine Society (NASS) meeting being held Sept. 25-28 in Chicago, and we can't wait to see all of our colleagues at the premier meeting for the spine market. To help you get ready for the meeting, Erin Dorgan, SmartTRAK Senior Analyst, Spine, has recorded a video update with the trends, key players and innovations to know before the show.

If you would like to see more of what SmartTRAK has to offer in spine market coverage, including some of our recent articles, or meet with us at NASS 2024,  just click the button below.

SmartTRAK takes a look at recent trends impacting the Foot & Ankle market.

As the first half of 2024 closes, SmartTRAK has observed a continued investment in the hallux valgus space. New implants and innovative instrumentation for hallux valgus procedures continue to push this segment to the forefront of the elective foot and ankle fixation space. While hallux valgus is front of mind for fixation, arthroplasty is also making waves as SmartTRAK continues to monitor toe replacement and advancements in ankle replacement.

As companies close out Q2 earnings, SmartTRAKcoverage has indicated slightly mixed results in the Extremities space. In this downloadable article, SmartTRAK examines recent trends impacting the Foot and Ankle market. including what's happening with hallux valgus procedures, which shows no signs of slowing down, and puts a spotlight on arthroplasty in the Foot &  Ankle segment

Click the button below to download and read the complete "Checking the Pulse of the Foot & Ankle Market" article by Natasha Weeks, SmartTRAK Managing Editor/Sr. Analyst Trauma & Extremities.

The 2024 HealtThe 2024 HealthpointCapital Investor Day is taking place on Friday, Sept. 13 in Las Vegas, and SmartTRAK will be there. Elise Wolf, SmartTRAK VP and GM of Orthopedics, has a new video update with everything you need to know before you go.

If you'd like to see more of what SmartTRAK has to offer in orthopedic coverage, including some of our recent articles on extremities, spine, enabling tech and total joints, just click the button below.

SmartTRAK is attending the upcoming American Orthopaedic Foot & Ankle Society Meeting (AOFAS), being held Sept. 11-14  in Vancouver, and we can't wait to see all of our colleagues at the premier meeting for foot and ankle. To help you get ready for the meeting, SmartTRAK's GM of Trauma & Extremities, Natasha Weeks, has recorded a video update with the trends, key players and innovations to know before the show.

If you'd like to meet with Natasha in Vancouver or just read more of SmartTRAK's coverage of the Foot & Ankle market, visit SmartTRAK Foot and Ankle Central.

Amaza Reitmeier, Medtronic’s VP and GM of Brain Modulation, discusses the company’s recent FDA approvals for asleep DBS and expanded MRI labeling, and provides an update on adaptive DBS in an interview with SmartTRAK. 

In an interview with SmartTRAK, Medtronic’s Amaza Reitmeier, vice president and general manager of Brain Modulation, discusses the company’s recent news in deep brain stimulation (DBS), including FDA approval for asleep DBS and MRI expanded labeling that allows patients to undergo additional scan time. She also provides an update on adaptive DBS (aDBS) and the ADAPT-PD trial, which is expected to support the global regulatory submissions to commercialize aDBS in patients with PD.  Medtronic recently filed for US FDA approval of aDBS.

Click on the following video to listen to the interview (14:32 minutes). A link to download a complete transcript of the interview is also provided below.
 

Interview Transcript

SmartTRAK: Hey everybody. Anne Staylor here with SmartTRAK. Today I get to talk to Amaza Reitmeier, the vice president and general manager of Brain Modulation at Medtronic. Hey Amaza, thanks for talking with me.

Amaza Reitmeier: Hi, Anne. Great to see you.

I know that you have some big news around DBS. You guys are advancing pretty quickly. The latest news involves FDA approval for asleep vs awake DBS, MRI expanded labeling, and then maybe you could give me an update on some other aspects of the adaptive DBS. So let's get started.

AR: Fantastic.

What is the significance? Talk a little bit about the FDA approval for asleep vs awake DBS, and why is that important? A lot of people are doing that. Just talk a little bit about the significance of that and what it means for Medtronic.

AR: Thank you, Anne. Well, first and foremost, you know from our prior conversations that we're very focused on the patient and making sure that patients have the best options available to them. While you're right that asleep DBS has been being done for years, it's actually been contraindicated in our labeling. The original labeling for DBS, which was established decades ago, required test stimulation to confirm that the therapy was working. But we also know that ...

Click the button below to download and read the full transcript of the SmartTRAK perspective article "Transforming DBS Therapy - An Interview with Amaza Reitmeier" conducted by Anne Staylor, SmartTRAK's Executive Editor and VP & GM of Neuro Therapies.

SmartTRAK's Anne Staylor, VP & GM Neuro Therapies, will be attending ESMINT 2024

SmartTRAK is excited to attend the ESMINT Congress 2024, which will be held at the Pharo Congress Center in Marseille, France, September 4-6. Anne Staylor, SmartTRAK VP & GM Neuro Therapies, will be there to cover the latest Neurovascular news and developments. In this Market Snapshot video update, Anne provides the latest research and technologies impacting the market for neuro intervention, including trends to look for at the meeting.

If you'd like to meet with Anne at ESMINT, or see more of SmartTRAK's neuro coverage, just click the button below to visit SmartTRAK Neurovascular Central.

Dr Stephen Snyder, MD, a renowned arthroscopic surgeon who now serves as the Medical Director for Pristine Surgical, discusses his experiences in the industry over the past 50 years.

In a recent interview with SmartTRAK, Dr. Stephen Snyder, a renowned arthroscopic surgeon who now serves as the medical director for Pristine Surgical, discussed his experiences in the industry over the past 50 years.

Click on the following video to watch the interview (58:52 min). For more details, interview topics by timecode are provided below. A link to download a complete transcript of the interview is also available below.

Interview Topics By Timecode:

00:50 Dr Snyder’s background.

08:02 The most notable advances that he saw during 40+ years in arthroscopy.

21:36 Some of the first arthroscopic repair procedures.

33:47 Using advanced technologies such as augmented reality.

39:17 The current state of industry meetings.

45:38 His role with Pristine Surgical and the advancing technologies in arthroscopic cameras.

Click the button below to download and read the complete transcript of the "Advances in Arthroscopic Innovation: An Interview with Stephen Snyder, MD" conducted by Andy Knapik, SmartTRAK Senior Analyst, Soft Tissue Fixation and Arthroscopic Enabling Technologies.

Andrew S. Murtha, MD addresses the controversy surrounding kinematic vs mechanical alignment in total knee arthroplasty.

Since the introduction of kinematically aligned knee arthroplasty in the mid-2000s, there has been controversy surrounding kinematic (KA) vs mechanical alignment (MA) in total knee arthroplasty (TKA). Kinematic alignment in total knee arthroplasty (TKA) attempts to restore natural limb alignment, maintaining the natural kinematic axis and ligament balance of the patient's knee. In contrast, the classic method of mechanical alignment aims to create a neutral hip-knee-ankle (HKA) axis. Advocates for KA say the technique intended to mimic a patient’s natural knee alignment will result in a more natural feeling and functioning knee. SmartTRAK had the opportunity to interview Andrew S. Murtha, MD regarding the growing interest in KA, what is driving this interest and what the future holds for KA vs MA with feedback from Benjamin Stronach, MD, associate professor at the University of Arkansas for Medical Sciences. Dr. Murtha is a board-certified orthopedic surgeon who is currently an adult reconstruction fellow at Houston Methodist Hospital. He is also a member of the American Association of Hip and Knee Surgeons’ (AAHKS) committee on Patient and Public Relations.

SmartTRAK: What has been your experience with kinematic alignment in total knee arthroplasty?

Andrews S. Murtha, MD: Kinematic alignment is a technical strategy in total knee arthroplasty that aims to individualize implant position by replacing only the cartilage and bone lost during the arthritis process. In its truest form, it does not place restrictions on the alignment of the components. I do not use an unrestricted kinematic alignment strategy in my practice, but the concept has expanded parameters for what is considered acceptable implant position.

In your estimation, based on your experience, what percentage of surgeons currently use KA vs mechanical alignment?

AM: In my experience, the majority of orthopedic surgeons use an adjusted mechanical alignment strategy. However, there does seem to be greater acceptance for slightly modifying the bone cuts to accommodate the patient’s native anatomy, thus reducing the need for large soft tissue releases to balance the knee. I would estimate that the percentage of surgeons using a truly unrestricted, caliper-based, resurfacing-type kinematic alignment strategy is relatively low.

What trends are you seeing in clinical practice – is KA increasing, decreasing or staying the same? What do you think is driving or limiting adoption?

AM: In general, interest in the kinematic alignment strategy has grown over the past 15 years. This interest seems to be driven by

Ariel Sutton, EVP and GM of Imperative Care’s Stroke business, discusses the Imperative Trial, the company’s Zoom Insert Catheters and more in an interview with SmartTRAK at SNIS 2024. 

Imperative Care’s Ariel Sutton, executive vice president and general manager of the company’s Stroke business, discusses results from the Imperative Trial, what it means for the acute ischemic stroke (AIS) market and the company’s newest innovations in an interview with SmartTRAK at the Society of NeuroInterventional Surgeons (SNIS) 21^st Annual meeting in Colorado Springs, CO held July 22 to 26, 2024.

To find out more, listen to the following video (15:54 minutes). A link to download the complete transcript of the interview is also provided below. 

Interview Transcript (scroll down to download the complete transcript)

SmartTRAK: Anne Staylor here with SmartTRAK. Today I am speaking with Ariel Sutton, EVP and GM of Imperative Care Stroke Business, live from the Society of NeuroInterventional Surgeons annual meeting in Colorado Springs. Ariel, thank you for talking with me today.

Ariel Sutton: Thank you for having me.

Let's start by having you talk about Imperative Care's presence at SNIS. What's important for us to know?

AS: We’re really excited to share the results of the Imperative Trial at SNIS this year. This is a 260-patient prospective trial across 26 centers in the US, evaluating the clinical benefits of the Zoom Stroke Solution, including aspiration with our Zoom 88 catheters. The results from the trial showed high reperfusion rates of 82.2% TICI 2B+, which is similar to previous studies that were submitted to the FDA for 510(k) clearance for reperfusion indication. There are a few metrics that we think are important to highlight from the trial. First is ...  

Click the button below to download and read the full transcript of the interview "SNIS 2024: An Interview with Imperative Care's Ariel Sutton" , conducted by Anne Staylor, SmartTRAK's Executive Editor and VP & GM of Neuro Therapies.

New partnership helps clients find and engage with physicians to accelerate product adoption and complements SmartTRAK’s expert market insights

SmartTRAK, the leading global Medtech business and market software intelligence solution in the Orthopedics, Wound Care, Regenerative Medicine and Neuro Therapy markets, announces a strategic partnership with Alpha Sophia, a leading Medtech commercial intelligence platform, to help clients quickly identify sales opportunities and position for growth in a highly competitive market.

As the trusted source for market intelligence, SmartTRAK now offers Alpha Sophia’s sales targeting capabilities on its real-time SaaS platform, creating a “one stop shop” for customers in need of actionable sales data plus market insights for strategic decision-making. The Alpha Sophia platform is an intuitive tool that enables commercial leaders to easily identify target physicians by region, site of care, specialization, procedure volume, social media presence and more. Comprehensive profiles of practitioners and organizations put unique insights at the fingertips of marketing and sales teams, enabling them to develop personalized engagement approaches.

Customers who access Alpha Sophia’s sales targeting solution through SmartTRAK’s platform will experience all the benefits of a comprehensive market insights solution, including

Arrests were made at the Phoenix Sky Harbor airport in June when two individuals attempting to flee the country were charged by the DOJ for defrauding Medicare over $900.0MM. According to the DOJ case summary, the two individuals “were charged by indictment with various counts of conspiracy, health care fraud, receiving kickbacks, and money laundering in connection with an alleged scheme to fraudulently bill Medicare $900 million for highly expensive amniotic allografts. The defendants targeted elderly Medicare patients, many of whom were terminally ill in hospice care, through their companies—Apex Mobile Medical LLC, Apex Medical LLC, Viking Medical Consultants LLC, and APX Mobile Medical LLC. “

SmartTRAK believes these charges are just the tip of the iceberg in terms of the amount of fraud occurring in the US Market for Skin Substitutes. With a dramatic spike in Medicare claims in 2023, it’s clear widespread Medicare abuse has allowed the US Skin Substitute market to balloon, almost doubling in just one year! The abuse is primarily limited to amniotic tissue products, which held 52.5% of the US market in 2022 and 64.5% of the market in 2023.

In this downloadable article, SmartTRAK discusses in detail the DOJ investigation and its impact on the Skin Substitute market, including:

• SmartTRAK Financial Analysis of the Market
• The Impact on Established Market
• Potential Drivers for Change
• Criteria for Medicare Physician Fee Schedule Focused (MPFS) Players
• What Could Impact the Market
• What the Future Holds

Click the button below to download and read the complete "Skin Substitute Market Rocked by DOJ Investigations" article by Susan Paquette, SmartTRAK VP & General Manager, Wound.  

Artificial Intelligence (AI) is transforming the medical device industry in myriad ways including enhanced diagnostics and imaging tools, more precise and consistent robotics and personalized medicine for improved patient care, and more. Where AI can also make a significant impact is in big data and predictive analytics by reducing staff administration, increasing efficiency and avoiding drowning in volumes of disparate data. But relying on AI alone for data and analytics has its pitfalls, especially when hallucinations occur resulting in flawed results and inaccurate predictions. That’s why having human experts behind the AI is critically important.

In this episode of DeviceTalks AI Podcast, Joe Mish, VP of Sales for SmartTRAK,  summarizes how SmartTRAK leverages AI tools alongside expert analysts to offer device customers one trusted source for market intelligence.  Joe discusses how Medtech customers rely on the unique, combined power of SmartTRAK’s Insights-as-a-Service platform and market and data experts to more quickly make strategic decisions around new product innovations and market expansions. With over a decade's worth of data and collective intelligence in the system, the predictive capabilities of AI and the power of non-hallucinating human insights, SmartTRAK might just be the “holy grail” solution. Just click the video below to listen in to learn more! 

A link to download the complete interview transcript is provided below.

0:00:00 Kayleen Brown: Hi everyone, I’m Kayleen Brown of DeviceTalks. Some exciting news to start. Our first four episodes of AI Meets Life Sci has more than 8500 plays. We’re so grateful that you’re interested in how AI is affecting our industry as much as I am. And as you probably noticed, we took a short break and we did that to speak to our audience in order to better understand how we can evolve that series, we learned two things. One, there’s an appetite for more artificial intelligence focused conversations. And two, we learned that though there’s an appetite for these conversations, there’s a hunger for these conversations to be specific to the medical device industry.

0:00:39 Kayleen Brown: So because of that, we’ve rebranded our series AI Meets Life Sci to DeviceTalks AI. DeviceTalks AI will feature exclusive conversations with the largest medtech OEMs and other industry stakeholders to better understand how they’re using artificial intelligence to reshape the industry. But you can still find us on every major podcast platform. Just search for DeviceTalks and make sure that you’re subscribed to DeviceTalks on YouTube.

0:01:06 Kayleen Brown: Today’s episode is extra special as we premiere under our new name. First, you’ll hear an interview with Joe Mish, vice president of sales at SmartTRAK. Joe reveals how SmartTRAK’s cutting-edge approach to market intelligence combines real-time analysis with the human touch of a world-class team. We will better understand how AI has helped speed up the market analysis process and how these technologies enhance strategic decision-making in market intelligence.

0:01:36 Kayleen Brown: After that is our keynote interview with Dr. Ha Hong, chief artificial intelligence officer at Medtronic Endoscopy. I’ll be joined by my AI Meets Life Sci co-host Brian Buntz, and we’ll discuss how Dr. Hong is integrating AI into Medtronic’s endoscopy unit, the potential impact of AI on healthcare outcomes, the importance of patient-centric AI design, and the promising future of AI in the medical device industry.

0:02:05 Kayleen Brown: As always, I’m so thankful for your continued support and I’m so excited about this new iteration of AI Meets Life Sci. Now, DeviceTalks AI. Again, we’re going to be specifically talking to medtech companies about how they’re integrating artificial intelligence for better health and business outcomes. So, let’s kick off our inaugural episode of DeviceTalks AI with my conversation with Joe Mish, vice president of sales at SmartTRAK.

0:02:36 Kayleen Brown: Joe Mish, vice president of sales for SmartTRAK Business Intelligence welcome to DeviceTalks AI. I’ve been so looking forward to sitting down with you and learning more about how artificial intelligence is integrating into the data world and helping our industry understand how the industry at large can look in the future. So with that, thank you again for joining us. I want to start at a 40,000 foot level, Joe.

0:03:05 Kayleen Brown: So can you tell our audience about SmartTRAK? What do you do and who do you serve?

0:03:11 Joe Mish: Absolutely. So SmartTRAK is a real time software as a service business intelligence platform. We provide rich market-level data, competitive intelligence and strategic insights to the medical device community. Essentially, we partner with medical device companies, OEM manufacturers, even financial service groups like VC and PE groups, as well as consulting organizations that really invest heavily in the medtech sector.

0:03:41 Kayleen Brown: I think your summary was a great high-level summary, but can you walk us through how real-time analysis is being conducted and ...

Click the button below to download the complete transcript of the interview featuring Joe Mish, SmartTRAK Director of Sales.

We are pleased to announce that John Hatchell has joined the team at SmartTRAK as Director of Sales for the Commercial team. John has 13 years of Medical Device sales and leadership experience within Orthopedics, helping to support trauma, joint replacement and robotics for Stryker and Biomet. Most recently, he has been the founder and CEO of TYDEi Health, a provider-focused business intelligence and optimization platform.

ASPN Chairman Tim Deer, MD, discusses the research and innovation at ASPN 2024 and the society’s collaborative approach to improving care for patients with chronic intractable pain in an interview with SmartTRAK.

Timothy R. Deer, MD, chairman of the American Society of Pain and Neuroscience (ASPN), discusses the society's goals, its rapid growth, and how ASPN is collaborating with different stakeholders to improve patient care and offer a wider range of new and innovative treatment options for patients with chronic intractable pain. To find out more, including what’s new in neuromodulation, minimally invasive spine and regenerative medicine, listen to the following video recorded live at the ASPN 2024 Annual Conference held July 11-14, 2024 in Miami Beach, FL. A link to download the complete transcript of the interview is also provided below. 

SmartTRAK: Anne Staylor here with SmartTRAK. I'm at the beautiful Fontainebleau Hotel in balmy Miami Beach, Florida at the American Society of Pain and Neuroscience Annual Conference. Today is the last day of the conference and I have the pleasure of talking with Dr. Tim Deer, the chairman of ASPN. Dr. Deer, thank you for talking with me today.

Dr. Tim Deer: Anne, thank you so much for having me. It's a great pleasure to talk to you and thank you for coming to our meeting.

Yes. Well, as you know, I think three years ago was the last time I was at your meeting, and I've had a colleague cover it who lives on the East Coast since then. Now I'm back covering the meeting and wow, has it grown exponentially since you and Dr. Sayed co-founded this meeting. I think this year, there's been a lot of energy and vibrancy around the content and in the exhibit hall and honestly, there's so much news for me to cover.

But before we get into the meeting, I thought it'd be a good idea to have you start by talking about the meeting itself, how it's grown, what the attendance has been this year, et cetera. And then what have been some of the key goals of society? And what have you and your vice chair, Dr. Sayed, been working toward as a society since you established the meeting?

Meet with SmartTRAK in Denver

The American Orthopedic Society for Sports Medicine (AOSSM) will hold its annual meeting in Denver, CO, from July 10-17, 2024. This meeting will bring together sports medicine physicians, clinicians and industry professionals and feature the latest research, cutting-edge updates and discussion on the future of sports medicine. SmartTRAK will be there.

Andy Knapik, SmartTRAK Senior Analyst, Soft Tissue & Arthroscopic Technologies, will be getting the scoop on what’s new at AOSSM and will be available to meet in person at the meeting. If you or your company have important news you’d like to share, or would like to learn more about SmartTRAK, please reach out to Andy at andy.knapik@smarttrak.com.

SmartTRAK has put together highlights of recent news in sports medicine to catch you up on the “news to know” before going to AOSSM 2024. The following is just a small sampling of recent news and SmartTRAK updates from around the world compiled, reviewed and posted in real-time every day by the expert analysts
at SmartTRAK.

New Products:

• Comparison Techniques For Medium To Massive Posterosuperior Cuff Tears
  

  Researchers look to prove that both transosseous-equivalent suture-bridge and independent double-row techniques provide comparable clinical results and retear rates for medium to massive posterosuperior RC tears. BMC Musculoskelet Disord

• Paragon 28*

  FNA mgmt highlighted five full launches YTD in 2024 in the high growth forefoot, minimally invasive and soft tissue markets including Grappler Knotless Anchor, Bridgeline Adaptive Tape, Mister Tendon Harvester, FJ200 Power Console and Burr System and PRECISION MIS Bunion System.

•  Stryker launches Citrefix Suture Anchor System
  

  Stryker announced the launch of Citrefix, a suture anchor system for foot and ankle procedures. The new system uses Citregen, a bioresorbable material designed to mimic the chemistry and structure of native bone. SmarTRAK reported on the Citrefix 510(k) approval in Feb 2021.

Patents:

•  Tissue Repair Devices and Methods

  US Patent “Tap-in bone anchor with expanding ring” was issued describing devices that can wrap around elongate tissue and are capable of supporting the tissue or keeping two severed ends in close proximity to one another. 12023030

• CONMED*

   CONMED's US Patent Application "MENISCAL TRANSPLANT SYSTEM" was published relating to a meniscal transplant workstation and accompanying tools for preparing a meniscal transplant and tibial surface and mounting the transplant to a tibia. 20240207068

• JNJ/DePuy Synthes*

  JNJ DePuy Synthes was issued US Patent “Methods And Devices For Repairing Meniscal Tissue” describing a suture anchor w/ an expanding ring that provides additional locking force for the device in bone. 12016545

Meet with SmartTRAK in Miami!

The American Society of Pain and Neuroscience (ASPN) will be holding
its 6th Annual Conference in Miami Beach from July 11-14, 2024, which
will feature the latest research, cutting-edge updates and discussion on
topics in pain and neuroscience.

SmartTRAK has put together highlights of recent news in SCS, PNS and
minimally invasive spine to catch you up on the “news to know” before
going to ASPN 2024. The following is just a small sampling of recent
news and SmartTRAK updates from around the world compiled,
reviewed and posted in real-time every day by the expert analysts
at SmartTRAK.

SmartTRAK’s Anne Staylor will be getting the scoop on what’s new at
ASPN, and will be available to meet in person at the meeting. If you or
your company have important news you’d like to share, please reach out
to Anne Staylor, SmartTRAK’s Executive Editor and VP & GM, Neuro
Therapies, at anne.staylor@smarttrak.com,

New Products:

• SPR Therapeutics' SPRINT extensa XT System with Bimodal PNS
  

  BSX was issued a US Patent, “Stimulation Modes To Adapt Customized Stimulation Parameters For Use In A Spinal Cord Stimulation System,” describing a graphical user interface to allow a pt to select a stimulation mode and predict optimal SCS parameters for personalized SCS.12017061

•  SiLO TFX* - Aurora Spine*

   Aurora Spine Corp. announced the successful use of SiLO TFX MIS Sacroiliac Joint Fixation Device in over a dozen patients, providing a minimally invasive surgical option for SI joint pain. Aurora estimates market opportunity > $2.3B/yr in the US and expects full launch by mid-year.

•  Inceptiv SCS: Offering Options in a Closed-Loop Device
  

  David Carr, Medtronic’s (MDT) VP and GM of Pain Interventions, discusses the company’s new Inceptiv SCS, what differentiates it from other SCS devices and what it means for MDT and the SCS market in an interview with SmartTRAK. Inceptiv SCS: Offering Options in a Closed-Loop Device

Patents:

• Nevro*

  NVRO’s US Patent Application, "Selective High-Frequency Spinal Cord Modulation For Inhibiting Pain With Reduced Side Effects, And Associated Systems And Methods," was published from 1.5 KHz to ~50 KHz SCS to treat LBP with reduced side effects.20240181258

• INBRAIN Neuroelectronics

  INBRAIN Neuroelectronics’ US Patent Application “SYSTEM FOR NEUROMODULATION APPLICATIONS” was published describing implantable and non-invasive wearable sensor-driven closed-loop neuromodulation systems that allow patient monitoring for PNS, VNS, DBS and SCS therapy. 20240207618

• SPR Therapeutics

  SPR Therapeutics was granted US Patent “Systems And Methods For Treating Shoulder Pain Related To Subacromial Impingement Syndrome” re one-time, continued or periodic PNS to neurological motor points of the posterior and middle deltoid muscles to mediate shoulder pain. 11944809

The proposed MAC LCDs for Skin Substitutes/CTPs was the hot topic of SAWC and will continue to be until the LCDs are finalized. In this article, SmartTRAK highlights new learnings from discussions at SAWC and the MAC open meetings.

The Symposium on Advanced Wound Care (SAWC) Spring 2024 meeting welcomed clinicians, researchers and industry to Orlando, FL, to learn, earn continuing education credits, share knowledge and network on the latest developments in advanced wound care. As is typical during SAWC, the Alliance of Wound Care Stakeholders also held a meeting of their members. With the Medicare Administrative Contractors (MACs) recently announced proposed changes in the Local Coverage Determination (LCD) governing Skin Substitutes/CTPs (cellular and/or tissue-based products), the Alliance pivoted and invited an expert to speak to the group about how the LCD process works and what laws govern what can be done at the MAC level versus the Center for Medicare & Medicaid Services (CMS) levels. Kudos go out to the team at the Alliance for bringing this meeting together. In addition to the Alliance meeting at SAWC, the MACs held open meetings for these LCDs from May 16 to May 29, and anyone, including manufacturers, could present comments, make a request and provide evidence. SmartTRAK participated in several of these meetings.

In this downloadable article, SmartTRAK gives an overview of LCDs, how they are drafted, the coverage limitations by wound type, issues surrounding evidence for inclusion on the covered list and an implementation timeline. For more information on what the proposed LCDs cover, see also “Medicare Administrative Contractors’ (MACs) LCD Changes: Impact on Skin Substitutes/CTPs.”

The following subjects are covered in detail in this downloadable article:

• The Process for Drafting LCDs
  As background, CMS governs the process for drafting the LCDs in their Medicare Program Integrity Manual (PIM) in Chapter 13, which was most recently updated in 2019 with almost every section re-written. These changes include ... (read more)
  
  
• Coverage Limitations
  The LCD is a literal guide to what is allowed and, conversely, what is automatically denied within the limits written in the LCD. The LCDs for Skin Substitutes/CTPs are for ... (read more)
  
  
• Missing or New Evidence and Reconsiderations
  One area that generated the most questions from manufacturers was how to address coverage decisions if the MAC working groups are missing recently published evidence or have evidence currently in development. The comment submission period was ... (read more)
  
  
• Timeline for LCD Implementation
  During the MAC open meetings, participants had several questions regarding the timeline for LCD implementation, and some requested a delay in implementation. The following timeline applies to all LCDs ... (read more)
  
  

" Perspective article by Jay Merkel, SmartTRAK Sr. Analyst.

INS President Dr. Marc Russo and INS President-Elect Dr. Konstantin Slavin discuss the current “state of the union” in neuromodulation, how the field is evolving and the challenges and opportunities that lie ahead in an interview with SmartTRAK at INS 2024.

At the 16th International Neuromodulation Society World Congress (INS 2024) held in Vancouver, Canada, Dr. Marc Russo, INS president, and Dr. Konstantin Slavin, INS president-elect, discussed the current “state of the union” in neuromodulation, how the field is evolving, where it’s going and trends in research, technology and clinical practice in an interview with SmartTRAK. They also discussed challenges and opportunities in the field, how the INS is addressing recent criticisms about neuromodulation and the promise and potential of neuromodulation across a wide range of clinical applications. 

To find out more, including the promising indications and areas of growth for spinal cord stimulation (SCS) and deep brain stimulation (DBS), click on the following video to listen to the interview recorded live at INS 2024 (51:53 min). Click hereto download a complete transcript of the interview. Topics by timecode are provided below. 

SmartTRAK highlights market and technology trends that will help drive growth in neurovascular interventions in 2024.

The neurovascular intervention market is poised for another exciting year in 2024, with key trends driven by an expanding treatable population and innovative technologies addressing critical gaps in patient care. The percentage of eligible acute ischemic stroke (AIS) patients who receive endovascular therapy (EVT) is projected to increase from ~25% in 2022 to ~40% in 2027E. According to the SmartTRAK US Mechanical Thrombectomy Market Overview, the market will generate a 5-year CAGR of 11.1%. Amidst market growth driven by treatment time window expansions, direct-to-EVT protocols and increasing evidence supporting EVT to treat large core stroke patients, SmartTRAK predicts continued advancements in three key areas: aspiration thrombectomy for ischemic stroke, automated stroke detection software and novel devices for treating intracranial aneurysms.

#1: Innovations to Increase Aspiration Efficiency
Aspiration thrombectomy is a mainstay of stroke treatment. With the increasing adoption of A Direct Aspiration, First Pass Technique (ADAPT), companies are innovating to improve aspiration efficiency, effectiveness, procedure speed, reperfusion and patient functional outcomes. SmartTRAK sees ... (read more)

#2 Accelerating Adoption of Automated Stroke Detection Technologies
Early and accurate stroke diagnosis is critical for timely intervention. Automated stroke detection software is gaining traction, with companies like Brainomix, RapidAI and Viz.ai leading the charge. Studies have shown that ... (read more)

#3 Aneurysm Treatment Beyond Flow Diverters
 While flow-diverting stents (FDS) remain a mainstay in treating intracranial aneurysms, SmartTRAK has witnessed the development of more novel devices catering to a broader range of aneurysm types and sizes since MicroVention introduced the Woven EndoBridge (WEB) device in 2011, the first intrasaccular device developed specifically for the treatment of wide-neck bifurcation aneurysms. This trend towards tailored solutions based on ... (read more)

The neurovascular intervention market is on an exciting trajectory, driven by increasing patient populations, innovative technologies and a focus on improving patient outcomes. 2024 promises to be a year of significant advancements in ... (read more)

Just click the button below to download and read the complete "Key Trends in Neurovascular Intervention for 2024" Market Outlook article by  Shelly Caruso, SmartTRAK Market Analyst/Associate Editor.

ISASS’s Morgan Lorio, MD, president-elect, discusses the obstacles to adopting emerging technologies in spine surgery and the importance of advocating for policy changes to support innovative treatments and improve patient outcomes in an interview with SmartTRAK.

Key topics discussed include ISASS’s successful efforts in addressing coding and reimbursement challenges to ensure access to innovative treatments for patients, the potential impact of artificial intelligence (AI) on reimbursement, the new ICD-10 codes for discogenic pain, regenerative spine treatments, future directions and initiatives for ISASS and fostering collaboration between industry stakeholders and surgeon societies.

Antimicrobial resistance (AMR) was directly responsible for 1.27 million deaths worldwide in 2019, according to the World Health Organization. With AMR now seen as a top global health concern and COVID-19 still in recent memory, the challenge of overcoming infections appropriately and effectively exists in all areas of healthcare and beyond. This includes wound care, with SmartTRAK forecasting that the WW antimicrobial market will exceed $1.00B for the first time in 2024.

One company aiming to tackle the challenge in antimicrobial therapies is Swiss-based Polaroid Therapeutics. The company has developed a proprietary advanced polymer technology that is designed to reduce bio-burden in a variety of settings, including in wound management. SmartTRAK recently caught up with CEO and co-founder Ran Frenkel to discuss the journey that the company has been on. Click on the video below to listen to the interview (15:01 min). A link to download the transcript of the interview is also provided below.

SmartTRAK: This is Kris Flinn with SmartTRAK. Today, I'm joined by Ran Frenkel, CEO and co-founder of Polaroid Therapeutics. Polaroid Therapeutics is a Swiss-based biotech startup focused on the development of innovative antimicrobial technology. The company has developed a proprietary advanced polymer technology that is designed to reduce bio-burden in a variety of settings, including in wound management. Ran, thank you for joining us today. Could you please start by giving me some background on yourself?

Ran Frenkel: Hi, Kris. Thanks. Happy to be here. I'm a pharmacist by training. For the last 25 years, I have been working in the pharmaceutical industry in different kinds of management positions in drug discovery and drug development. For the last 11 years, I was the Chief Development Officer of an oncology company here in the US, where we developed a first-in-class new drug for blood cancers, which was approved in over 50 countries. For the last two years, nearly two years, I joined Polaroid Therapeutics, moving from the oncology space into more of the antibacterials and wound management space.

Fantastic. So, Polaroid is a name that many people will recognize, but could you tell me a little about Polaroid Therapeutics specifically and the journey that the company's been on?

RF: Yeah, and it's a very nice story because everyone is familiar with ...

It is difficult to make it as a small to midsize company in the Global Wound Care Market, which was painfully evident for a few Swedish companies in the fall of 2023. SmartTRAK looks at lessons learned and explains why the future is still bright.

Sweden is traditionally a great place to start a wound care company. Several established global leaders are based there, like Mölnlycke*, Essity* and Arjo*. They fund early-stage companies and act as a source of skilled personnel. Strong universities and leading pharma and medical device companies also contribute to a dynamic market.

In the fall of 2023, not one, not two, but three Swedish companies found themselves in deep trouble. RLS Global filed for bankruptcy, Promore Pharma was liquidated and S2Medical was under reconstruction. In this article, SmartTRAK looks deeper at those companies, what went wrong, and highlights a few startups embarking on the journey. Lessons learned are not limited to the Swedish market but apply everywhere.

The companies covered in detail in this comprehensive Market Perspective article, which can be downloaded in its entiretyhere, are:

• Companies in Trouble
  • RLS Global*
  • Promore Pharma*
  • S2Medical*
• Successful Startups
  • Abigo Medical*  
  • Absorbest*
• Other Startups
  • Amferia
  • Ilya Pharma
  • Colzyx 
  • PressCise
  • ViTri Medical*
  • Odinwell
  • Dermicus
  • Seber Medical

Although the fall of 2023 was challenging for a few companies, the future looks bright for Sweden to maintain its position as a strong generator of ...

* These links can only be accessed by SmartTRAK subscribers. To learn more            about SmartTRAK and how to subscribe, scroll down.

Adam Hattan, VP of marketing for Route 92 Medical, discusses the SUMMIT MAX trial and provides an update on the company and products in an interview with SmartTRAK.

Route 92 Medical (R92) is raising the bar and advancing the treatment of acute ischemic stroke through its 250-patient SUMMIT MAX clinical trial, the first randomized controlled trial to evaluate the safety and effectiveness of “super-bore” 0.088” aspiration catheters. The company recently announced enrollment is complete in SUMMIT MAX, which features the company’s Monopoint Reperfusion System, including the HiPoint 88 and HiPoint 70 Reperfusion Catheters and the Tenzing Catheters. HiPoint is currently approved by the FDA as an access catheter, but the company plans to submit the results of SUMMIT MAX to the FDA to obtain the NRY indication, which would allow physicians to use the device on label as an aspiration catheter.

For an update on R92, its products and what SUMMIT​ MAX means for the company and market, SmartTRAK interviewed Adam Hattan, R92’s vice president of marketing. Click on the video below to listen to the interview, recorded via Google Meet (19:48 min). A link to download the complete transcript of the interview is also provided below.

SmartTRAK experts across orthopedics, sports medicine, spine and enabling technology attended this year’s 2024 Canaccord Genuity Musculoskeletal and American Academy of Orthopedic Surgeons (AAOS) annual conferences. Held from February 12-15 in San Francisco, CA, these gatherings brought together the top minds in the industry. In this post, we share some key insights and updates gleaned from these conferences, offering a glimpse into the latest trends and innovations shaping the future of orthopedic and musculoskeletal care.

• MARKET

Maxx Orthopedics*
SmartTRAK learned at AAOS 2024 that Maxx Medical is going on the offensive to grow its joint replacement business in the US and that the Company plans to launch new hip and knee products in 2024.

Paragon 28*
At AAOS 2024, Paragon 28 noted that its supply chain issues have resolved and does not expect a headwind this year. As a result, Needham believes the company can return to ~20% revenue growth in 2024.

restor3d*
Restor3d reported it currently has 157 active distribution partners calling on ~22,965 orthopedic surgeons and ~18,000 podiatrists. Management noted surgeons will bring difficult cases and from there restor3d can create additional sales opportunities. CG 2024 Musculoskeletal Conference

• REVENUES

BONESUPPORT*
BONESUPPORT highlighted the continued strength of Cerament G in North America with approximate revenues of $17.0MM in Q323 since launching in June 2023. CG 2024 Musculoskeletal Conference

OrthAlign*
At AAOS 2024, SmartTRAK learned that OrthAlign’s 2023 revenue was up +25% to $51MM, led by strong adoption of its Lantern next-generation handheld navigation system and increasing use of the Balance gap balancing feature on Lantern Knee. The company noted +37% growth in the ASC setting.

SmartTRAK takes a look at the trends impacting the Extremities Market in 2024 and beyond.

Among the many topics covered in detail in this market outlook article are:

• CMS Reimbursement Changes Accelerate Shift to Arthroplasty Site-of-Care
  The Centers for Medicare and Medicaid Services’ (CMS) move to reimburse shoulder replacement and ankle replacement in an ambulatory surgery center (ASC) setting will accelerate the move of procedures to ... (read more)
  
  
• An Increase in Pricing Pressure from the Shift to Shoulder ASC Procedures
  The national average CMS facility reimbursement in 2024 for total shoulder arthroplasty in an ASC is approximately $14K, significantly lower than for hospital-based procedures in the range of ... (read more)
  
  
• The Race is on for Shoulder Robotics
  Stryker and Zimmer Biomet appear to be racing to the finish line to be the first to market in the US with a shoulder robotics solution. During Zimmer Biomet’s Q323 earnings call, CEO Ivan Tornos stated they plan to be first on ... (read more)

From OEM manufacturers getting dressings approved in the US to pressure injury prevention focus - SmartTRAK takes a closer look at what to keep an eye on in 2024.

SmartTRAK forecasts the WW Advanced Wound Dressing Market will grow at a 5-year CAGR of +5.2%. The market grew +5.2% in Q323 and +5.6% in the first three quarters of 2023. Advanced Wound Dressings is a market spread relatively evenly across geographies, with Europe currently representing a 44.1% share of the 2023 worldwide (WW) market, the US representing 27.9% and the ROW 28.0%.

Looking ahead, SmartTRAK sees three trends continuing in 2024. They are:

• Growing Use of OEM Manufacturers in the US
  In the US, most dressings require 510(k) clearance by the FDA. A strong trend in recent years is that original equipment manufacturer (OEM) providers have been getting their products approved for sale in the US and then ... (read more)
  
  
• Major Players Investing in Infrastructure
  Another trend of interest is more activity than usual from leading companies investing in infrastructure. SmartTRAK examines recent events and the potential drivers behind those decisions ... (read more)
  
  
• Growth in Dressings for Pressure Injury Prevention
  SmartTRAK expects the use of dressings for pressure injury prevention to be a key growth driver in the Advanced Wound Dressing Market in the coming years. The trend is supported by an increasing body of evidence indicating that ... (read more)
  

SmartTRAK has developed an in-depth analysis of the pressure injury prevention market, including the market size for the US, Europe, and the rest of the world (ROW), five-year forward forecasts, clinical and laboratory evidence, key drivers of market growth, and product technologies and claims. To find out more, please click here.

To download and read the complete "Advanced Wound Dressings: 2024 Market Outlook" by Lennart Stadler, SmartTRAK GM, OUS & Sr. Analyst, Wound and Anikó Szekér, SmartTRAK Sr. Analyst, Wound, just click the button below.

Rich ongoing data updates and comprehensive expert analyses will deliver evolving market trends and conditions for wound care professionals.

MALVERN Pa., (February 15, 2024) — HMP Global’s Wound Care Learning Network (WCLN) today announced a partnership with SmartTRAK, a comprehensive life sciences market intelligence solution providing real-time market data and analysis along with expert insight on evolving trends and conditions of interest for wound care professionals.

With the eyes of the wound care world focused on the markets for Skin Substitutes and Antimicrobials, SmartTRAK discusses how 2024 could be a disruptive year for Debridement.

SmartTRAK forecasts that the WW Debridement Market will grow at a 5-year CAGR of +4.9% to 2027E, at which point it will be valued at over half a billion dollars. In this article, Kris Flinn, SmartTRAK's Sr. Analyst, Wound, does a deep dive into what's ahead for the debridement market, including the indexed growth for Advanced Wound Care (AWC) and Debridement for each of the three SmartTRAK geographical regions: US, Europe (EU) and the Rest of World (ROW).

Among the topics covered in detail in this market outlook article, which can be downloaded here, are:

• Chemical Debridement Growing Pains
  Chemical Debridement is the smallest of the Debridement segments The WW 5-year CAGR of +69.1% promises a brighter future, with usage growing across all geographic regions, including ...
• New Enzymatic Debridement Technologies Continue to Build Evidence
  MediWound presented Phase IIB clinical trial results for bromelain-based EscharEx at the SAWC Spring meeting in May 2023. The 120-patient venous leg ulcer, multicenter, randomized control trial compared EscharEx with a placebo gel vehicle and a non-surgical standard of care (SoC). Results showed...

Medtronic executives discuss how the Company is making waves in interventional pain, minimally invasive spine and deep brain stimulation in an interview with SmartTRAK at NANS 2024.

Medtronic’s David Carr, vice president and general manager of Pain Interventions, and Amaza Reitmeier, vice president and general manager of Brain Modulation, discuss the Company’s latest news, research and innovation in an interview with SmartTRAK at the North American Neuromodulation Society (NANS) 2024 Annual Meeting held January 18-21 in Las Vegas, Nevada.

To find out more, including the Company’s priorities and vision for interventional pain, minimally invasive spine and deep brain stimulation, click on the following video to listen to the interview (32:30 min). Topics by timecode are provided below, and you can click the button to download a transcript of the interview.

Interview Topics by Timecode:

00:27 David Carr introduction and background. Overview of Medtronic’s top news at NANS and the importance of the Company’s broad portfolio of pain intervention solutions, including stimulation, targeted drug delivery and interventional spine. 

04:28 Overview of Medtronic’s presence at NANS regarding clinical and scientific research vs competitors. Highlights of clinical data from Australian ECAPs study to support the introduction of the Inceptiv Spinal Cord Stimulation (SCS) system, what’s next for Inceptiv and how Inceptiv differs from other ECAP-based SCS devices. Discussion of other research and evidence to support expanded indications and health economics. Company strategies for leveraging data to drive adoption, reimbursement and growth in non-surgical refractory back pain and diabetic painful neuropathy (DPN),

Throughout 2023, SmartTRAK led the way in helping you Be The Expert in the MedTech industry. Serving as your trusted resource for the latest industry developments, we provided real-time market data and analysis across the orthopedic, wound care, regenerative medicine and neurotherapy sectors.  Presenting SmartTRAK's Top 12 Blog Posts from 2023, featuring indispensable insights from our expert analysts.

1. Could Reverse Hips Change the Total Hip Game?
   Hip Innovation Technology is betting on its Reverse HRS Hip to change the practice of total hip replacement
   
   
2. Three Ortho Robotics Companies to Watch in 2023
   SmartTRAK identifies three orthopedic robotics companies strategically positioned to shake things up this year in the fast-growing robotic-assisted TJA market.
   
   
3. Saluda Medical: Changing the Game in Spinal Cord Stimulation
   Saluda Medical President and CEO Jim Schuermann discusses the Company, the Evoke System and changing the game in SCS in an interview with SmartTRAK.
   
   
   
   

SmartTRAK talks with Hybrisan CEO Dr. Mortimer to discuss the challenge of biofilms and the Company’s journey to bring its WoundSan technology to market.

The AWC Summit, held biannually, brings together established companies, start-ups, research organizations and various industry stakeholders. SmartTRAK previously covered the US event in July 2023 in Boston, MA, focusing on advancing the commercialization of new technologies in wound care, and was in London, UK to cover the EU Summit. 

A regular feature of the Advanced Wound Care (AWC) Summit is the Innovation Showcase. At the event in London, six companies took turns pitching their technologies, with the delegates voting to award one company as the winner.
Following the vote, the winning organization was announced as Hybrisan. SmartTRAK talked with Hybrisan CEO Dr. Mortimer to discuss its Woundsan technology and the challenge of combating biofilms in wound care. The interview can be viewed below and a transcript can be downloaded by clicking the button:

Future Events

The next AWC Summit will be the US edition and will take place in Boston, MA on the 16^thand 17^thof April, 2024. SmartTRAKwill be in attendance and will be discussing the latest insights within wound care. More information on the event is available  here. The next European event is planned for late 2024, with details to follow.

MIAMI, FLORIDA — We are thrilled to announce that SmartTRAK's Susan Paquette, VP of Wound Care, will be speaking at the inaugural Cellular, Acellular and Matrix-like Products (CAMPs) Wound Care Summit 2024, set to take place on March 13-14 in the vibrant city of Miami. This two-day clinical and scientific summit aims to empower physicians and wound care professionals to achieve optimal outcomes, strategize for regulatory approval, and navigate reimbursement processes for CAMPs.

The North American Neuromodulation Society (NANS) is celebrating its 30^th anniversary in 2024 and is once again bringing together the leading clinicians, researchers and manufacturers to Caesar’s Palace in Las Vegas for the NANS 2024 Annual Meeting, to be held January 18-21. To get you up to speed before the meeting, SmartTRAK has put together highlights of recent neuromodulation news. The following is just a small sampling of recent Neuromodulation-related news and updates from around the world compiled, reviewed and posted in real-time every day by the expert analysts at SmartTRAK.

SmartTRAK will be attending NANS 2024 from January 18-21. If you'd like to meet with us in person, please reach out to Anne Staylor, SmartTRAK’s Executive Editor and VP & GM, Neuro Therapies, at anne.staylor@smarttrak.com, or just click the button below.

SmartTRAK highlights start-ups developing innovative products for joint resurfacing, soft tissue fixation, ligament and tendon augmentation at the 2023 MNVC.

Sports medicine and extremities were prominent themes at the 21st Annual Musculoskeletal New Ventures Conference (MNVC) held in Memphis in November 2023. Approximately one-third of the 38 presenting companies debuted new and innovative technologies for treating sports-related injuries of the knee, shoulder, hand, foot & ankle ranging from soft tissue fixation, ligament and tendon augmentation and cartilage resurfacing. Now that investment in robotics and surgical navigation craze has peaked, major orthopedic manufacturers are directing research and development (R&D) dollars toward restoring joint function using biological approaches and a variety of less invasive techniques. 

Among the topics covered in this market outlook article are:

• Promising Knee and Shoulder Start-Ups
• Extremity Fixation: An Emerging Market
• Resurgence in Joint Resurfacing

A fertile ground for strategic negotiations and deal-making, several of the major players have broadened their range of products through strategic tuck-in acquisitions in the past year. Also, several start-ups are targeting the multi-billion dollar Soft Tissue Fixation market.  This landscape reflects a dynamic and competitive environment where established players seek to strengthen their positions through ...

To download and read the complete "Sports Medicine and Extremities Start-Ups to Watch" market outlook article by Sharon O'Reilly, SmartTRAK's Founder and CEO, just click the button below.

SmartTRAK attended key sessions on ADM use and reports on the latest trends impacting the US Breast Matrices Market.

The American Society of Plastic Surgeons (ASPS) and various manufacturers continue to pursue IDEs to gain an indication to use an acellular dermal matrix (ADM) in breast reconstruction. At Plastic Surgery: The Meeting 2023 (PSTM2023), held in Austin, TX, SmartTRAK attended key sessions on ADM use and reports on the latest trends affecting the market for ADMs.

In this article, SmartTRAK discusses the evolution and growth of ADMs and shares observations from the meeting across primarily two sessions covering breast reconstruction: They are:

• “Support Group: A Mesh For Each Patient and Getting Away Without It”
• “Back to the Future: Moving Forward or Going Back with Pre and Subpectoral Reconstruction.”

Just click the button below to download and read the complete detailed "Plastic Surgery: The Meeting 2023" article by Doug Devens, SmartTRAK's IT Product Director and Sr Analyst, Wound.

Over the last 10+ years, the market for skin substitutes has been turbulent with new technologies and products being launched and reimbursement changes occurring for the various sites of care. SmartTRAK highlights a few of these based on the recent SAWC Fall meeting.

Skin substitutes, also referred to as CTPs (cellular and/or tissue-based products) or CAMPs (cellular, acellular and matrix‑like products), remained front and center at the Symposium on Advanced Wound Care (SAWC) Fall meeting held in Las Vegas on November 2-5, 2023. The strong presence of these products mirrors a similar trend in the overall US Advanced Wound Care (AWC) market. For Q323, skin substitutes alone account for 37% of the US AWC market, more than Negative Pressure Wound Therapy (NPWT) or Advanced Dressings, according to an analysis of SmartTRAK Financial Dashboard.

In this article, SmartTRAK discusses in detail:

• The Migration of Skin Substitutes Over the Years
• Which Synthetics are Gaining Attention
• New Companies–Unique Technology and Innovations
• Health Policy Dynamics–Reimbursement and Advocacy
• The Future of US-Based AWC Companies
• The Potential for Acquisitions on the Horizon

To download and read the complete detailed "SAWC Fall 2023: Skin Substitutes Reign Again" article by SmartTRAK's Susan Paquette, VP & General Manager, Wound and Terry Hayslett, Sr. Analyst, Wound, just click the button below.

SmartTRAK was on-site at NASS 2023 covering the latest spine trends including hosting the hottest reception in town, “Targeting the ASC, What Spine Companies Need to Know."

Shifting hospital-based procedures to the ambulatory surgery center (ASC) is one of the biggest opportunities for healthcare savings and the opportunity is especially great for spine given its high acuity procedures like lateral lumbar fusions, 360 fusions and total disc replacements (TDRs) according to the results of SmartTRAK’s recent survey of 30 ortho, spine and neurosurgeons. At this year’s North American Society (NASS) Annual Meeting held in Los Angeles, CA October 18-21, SmartTRAK hosted a standing-room-only reception for industry on the migration of spine procedures into the ASC titled “Targeting the ASC: What Manufacturers Need to Know,” which included panel discussions and presentations focused on the spine market and practice trends. In this article, SmartTRAK highlights the top takeaways from the reception and identifies the latest trends and innovations at NASS affecting growth in the US Spine Market. Topics covered in the article include:

• New Care Models Optimizing Outpatient Spine
• The Motion Preservation “Renaissance” was Hard to Miss
• MIS SI Joint Fusion Systems – A Plethora of Systems, New Devices Launching Ahead of 2024 Reimbursement Changes.
• Will New Interbody Technologies Displace the Need for Biologics?
• Deals Abound: Several Biologics Deals Announced at NASS and After

To download and read the complete "NASS 2023: Trends, Advancing Technologies and New Deals Shaping the Future of Spine" article by Kris Jacques,  SmartTRAK's GM, Spine, just click the button below.

Nevro* (NVRO) announced it acquired VYRSA Technologies*, a privately held company focused on the minimally invasive treatment of chronic sacroiliac joint (SI Joint) pain. According to the Company, VYRSA is the only SI joint company that manufactures and supports a complete portfolio of FDA-cleared, state-of-the-art SI joint fusion devices. The acquisition was signed and closed on Nov 30, 2023. 

NVRO paid $40MM at closing and agreed to pay up to an additional $35MM in cash or stock tied to milestones. NVRO CEO Kevin Thornal said VYRSA offers differentiated implants to the Company’s current call point of physicians and will help drive company growth, adding that the technology will help bring long-term pain relief to the 15-30% of people suffering with chronic low back pain associated with the SI joint.

The US MIS SI Joint Fusion Market is the fastest-growing segment in the US Spine Market and a growing number of pain physicians are performing these procedures. According to SmartTRAK’s recently published 2023 US MIS SI Joint Market Report, this market is projected to grow at +18% CAGR over the next five years and 53+ MIS SI Joint Fusion systems are now commercially available in the US. See 2023 MIS SI Joint Fusion Market Report*.

The Company also announced the closing of a six-year, $200MM term loan credit facility to be used to repurchase the majority of its 2025 Convertible Notes and for working capital and other corporate purposes. NVRO CFO Rod MacLeod noted that the Company was pleased to refinance a majority of its debt and push the maturity out to 2029 while limiting equity dilution to 2.6MM warrant shares. 

Ready to dive into one of the most rapidly expanding markets in the world of Spine? Welcome to the realm of SI Joint Fusion, a market poised for remarkable growth with a projected 5-year CAGR of +18%. At SmartTRAK, we’re excited to introduce you to this thriving sector and give you a sneak peek of our forthcoming in-depth market segment solution subscription.

Outlined below is a brief list highlighting some of the key insights awaiting you upon subscribing to SmartTRAK's innovative solution and the valuable knowledge it delivers:

• Market Overview (US only/MIS market only):
  - Incidence and Prevalence: Understand the scale of SI Joint Fusion cases.
  - Market Size: Explore the market's current size and potential.
  - Revenue/Procedure Forecast through 2027: Take a look at expected future growth by market segments; transfixing and non-transfixing.
  - Growth Trends: Stay ahead with insights into emerging trends.
• Competitive Landscape:
  - By System Type: Discover the differences between Transfixing and Non-transfixing.
  - 2022 ASP Data Summary: Gain access to crucial pricing information.
• National/Regional Site of Service Procedure Volume Data:
  - HOPD vs ASC vs. Inpatient: Know where these procedures are performed.     - Annual Trends from 2017: Track the historical data for insights. 
• Coding & Reimbursement - 2024 Outlook:
  - Anticipate changes in coding and reimbursement for the coming year.
• Why MIS SIJ Fusion Matters:
  Within the vast Spine landscape, the Minimally Invasive Surgery (MIS) SI Joint Fusion procedure category is the star of the show. Here's why:
  - Growing Awareness and Diagnosis: More individuals are recognizing SI joint pain as a significant issue.
  - Robust Clinical Data: The body of clinical evidence is expanding.
  - Increasing Reimbursement Coding: Hospitals, HOPDs, ASCs and Physician's offices.
• The Future of MIS SI Joint Fusion:
  Acceptance of the posterior/dorsal non-transfixing MIS SI fusion approach is on the rise. This process is set to drive procedural growth and popularity, particularly among interventional pain physicians at Ambulatory Surgical Centers (ASCs).
  
  

So are you ready to dive into one of the most rapidly expanding markets in the world of Spine? Don’t miss your chance to stay ahead of the curve in the booming world of SI Joint Fusion and Be The Expert! Just click the button below to find out more.

Three MACs rocked the Skin Substitute/CTP market with changes in coverage in their final LCDs implemented in September. SmartTRAK takes a look at the overall impact on the market.

SmartTRAK has covered the highly active, ever-growing Skin Substitute/CTP market for over ten years. During that time, the market has grown at a CAGR of over +13%. Most years it experienced strong double-digit growth except those years impacted by reimbursement changes, Department of Justice (DOJ) investigations or the COVID-19 pandemic. Skin Substitute/CTPs are primarily used on Medicare patients with non-healing diabetic foot ulcers (DFUs) and venous leg ulcers (VLUs). The Center for Medicare & Medicaid Services (CMS) primarily pays for health care services for people aged 65 and older. Individuals can receive health care benefits via traditional Medicare or Medicare Advantage, which is run by private health insurance plans. Traditional Medicare contracts with Medicare Administrative Contractors (MACs) to process claims for reimbursement and write local coverage determinations (LCDs). Currently, there are twelve regions in the US managed by seven MACs.

Among the topics covered in this extensive article are:

• Key Policy Changes
• Impact on Patients
• Market Impact

On August 3, 2023, three MACs issued final LCDs governing the use of Skin Substitutes/CTPs in treating DFUs and VLUs. The release of the final LCDs, which are effective September 17, 2023, was not surprising to the market, given that the proposed LCDs were issued in 2022. The proposed LCDs allowed ...

To download and read the complete "Impact of Medicare Administrative Contractor LCD Changes on Skin Substitute/CTP Market" article by Susan Paquette, SmartTRAK's VP & General Manager, Wound and Terry Hayslett, Sr. Analyst, Wound just click the button below.

SmartTRAK's Elise Wolf, Vice President and General Manager of Orthopedics, Digital and Quality, along with Beth Roach, Director, Data Strategy, will be discussing new trends in Ambulatory Surgical Centers (ASC) and effective targeting strategies at the 2023 Musculoskeletal New Ventures Conference (MNVC) on Nov 14-15 at the FedEx Institute of Technology in Memphis, TN. They will also delve into a detailed case study on ASC builds. Their presentation is titled "Targeting the ASC: Essential Knowledge for Orthopedic Companies." Make sure you don’t miss out on Elise and Beth's expert insights!

At the 20th World Congress of the International Union of Phlebology, SmartTRAK identifies market developments that will impact the treatment of venous and lymphatic diseases now and in the future.

The American Vein and Lymphatic Society recently hosted the 20th World Congress of the International Union of Phlebology (UIP 2023) in Miami Beach, FL. The Congress drew clinicians from around the world to discuss the latest advances in venous and lymphatic medicine. While the Congress covered many interesting topics, SmartTRAK noted market developments that will impact the treatment of venous and lymphatic diseases now and in the future. In this article, SmartTRAK explores the impact that the Centers for Medicare and Medicaid Services (CMS) reimbursement cuts are having on physicians treating venous and lymphatic diseases, examines how clinicians and industry are responding to the proposed Medicare coverage of lymphedema treatment items and evaluates what’s on the horizon for emerging technologies. 

This downloadable article, discussing the market developments that will impact the treatment of venous and lymphatic diseases now and in the future, delves into many compelling topics, including:

Physician Payment Cuts
The American Medical Association reported that between 2001 and 2023, the cost of operating a medical practice increased by 47%, while physician payment rates increased by only 9%. When adjusted for inflation, the rates have gone down by 26%. Dr. John Blebea, Vascular Surgeon and Clinical Professor of Surgery at Central Michigan University, underscored this point with a presentation titled “The Effect of Medicare Physician Reimbursement Cuts on Office-Based Practices.” Dr. Blebea noted that ...

New Medicare Coverage of Lymphedema Treatment Items
Medicare currently provides Durable Medical Equipment (DME) coverage or authorizes payment for certain compression items when used to treat venous stasis ulcers. However, Medicare does not provide coverage for many of the same items when they are used to treat lymphedema. This dynamic provides a great case study of the effectiveness of advocacy in calling for ...

Emerging Technologies
If innovation fuels growth in the med tech industry, then the number of sessions on emerging technologies at UIP 2023 should mean that the future is bright for venous and lymphatic medicine. Dr. Steve Elias, Director, Center for Vein Disease, Englewood Health Network, hosted several sessions on emerging innovations in thrombectomy, sclerotherapy, artificial intelligence (AI)-guided imaging, intravascular ultrasound and compression therapy. SmartTRAK has covered the Compression Therapy Market since 2015 and has watched ...

To download and read the complete article about The Future of Venous and Lymphatic Medicine by Terry Hayslett, SmartTRAK Senior Analyst, Advanced Wound Care, just click the button below.

New SaaS technology offering delivers competitive advantage in rapidly changing Ambulatory Surgery Center market.

SmartTRAK, the leading global Medtech business and market software intelligence solution in the Orthopedics, Wound Care, Regenerative Medicine and Neuro Therapy markets, announces the release of enhanced software products and strategic reports available for purchase in Q4 to help clients position themselves for growth in 2024 and beyond.

SmartTRAK takes a quick look at recent trends that may influence the Total Joints Market in the near and long term

Wall Street Analysts recently called out two trends specifically that could influence the Total Joints Market. One trend, the strengthening of the US dollar, is likely to impact the global market in 2024. Another trend is the increased prescribing of GLP-1 drugs, such as Ozempic, Wegovy, Byetta and Mounjaro, medications first used to treat Type 2 diabetes, as a treatment for obesity. This has the potential to impact the market down the road. In this downloadable article, SmartTRAK maps out the potential impact of these trends.

To download and read the complete article by SmartTRAK's Lisa Mahan, Product Development & IT, Sr. Analyst TJ&E, just click the button below.

Medtronic Neurovascular President Dan Volz discusses expanding patient access to neurovascular therapies through innovation and globalization in an interview with SmartTRAK.

Medtronic Neurovascular President Dan Volz discusses innovation, globalization and the Company’s plans to double the number of neurovascular patients treated annually in three years in an interview with SmartTRAK. Volz said the Company is driving growth in Neurovascular through innovative business models and strategic investments in remote connectivity and the Medtronic Neurovascular Co-Lab Platform, a novel incubator designed to accelerate innovation in stroke care and treatment. To find out more about the Company and its latest innovations, click on the video to listen to the full interview (27:30 min). To download a transcript of the complete interview, just click the button below.

Anne Staylor here with SmartTRAK. Today I have the pleasure of interviewing Dan Volz, president of Medtronic Neurovascular. Dan, thank you for speaking with me today.

Dan Volz: It's my pleasure. It's good to talk to you.

I haven't talked to you for a while and I was hoping to catch up with you at SNIS when it was here in San Diego. Now that we are talking, let's just start broadly and talk from your perspective, what's important for us to know about Medtronic Neurovascular and what are your top priorities for fiscal year 2024?

DV: It's good to see you and I'm sorry that I missed you down in San Diego. That was a pretty quick up and back for me, but for us obviously it's about the patients and we had a pretty important milestone in 2022. In a 12-month period we helped treat 250,000 people, so that was a great celebration for us as a business. But I think even more importantly, it kicked off our strategic planning process to double that number in three years. And so everything that we do is centered on how do we drive toward that number? And there's a lot that goes into that, but it starts with obviously innovation and how are we innovating in our portfolio? What are we doing organically and what are we looking at inorganically to drive toward that number? And you know these statistics as well as anyone, there's 15 million strokes and we only treat five to 600,000 of them a year ...

To download and read the transcript of the complete interview with Dan Volz, president of Medtronic Neurovascular, by SmartTRAK's Anne Staylor, Executive Editor, VP & GM of Neuro Therapies, just clickthe button below.

Fertram Sigurjonsson, CEO of Kerecis, discusses the recent acquisition, how the Company has evolved over the last decade and key milestones along its “Road to Success” in an interview with SmartTRAK.

Increasing acceptance of diagnostics, as well as the repositioning of existing technologies, could help drive growth in European wound care.

Pressure injuries are globally accepted as a major healthcare challenge. SmartTRAK estimates there were 10.2MM pressure ulcers in Europe in 2022, with 4.0MM being stage III or IV. At the 23rd European Pressure Ulcer Advisory Panel (EPUAP) meeting recently held in Leeds, UK, the main focus of the meeting was on diagnosing and treating the more challenging stage III/IV pressure ulcers. In this downloadable article SmartTRAK explores how diagnostics continues to be a major driver of innovation within the space and how companies and products previously focused on treatment are now firmly positioning themselves within the prevention space, where SmartTRAK will soon offer brand-new insights.

Among the many topics covered in the article are:

• Diagnostics
  The perception of diagnostic tools within European wound care appears to be evolving. Previously, they had been viewed as aspirational but unaffordable luxuries, but are now becoming ...
  
  
• Wound Treatments
  There was a distinct lack of new technologies for the treatment of pressure injuries on display in the exhibition, with existing dressings and negative pressure wound therapy (NPWT) being the main solutions on stands. New treatment solutions were ...
  
  
• Dressings for Pressure Injury Prevention
  Historically, clinicians have used dressings designed for managing open wounds as a method of pressure injury prevention. In the last decade, more and more dressings companies have been recognizing the possibilities offered within this market. Published evidence suggests ...
  
  To download and read the complete "Prevention Proves Better than Cure for European Dressing Companies" perspective article by SmartTRAK's  Aniko Szeker, Sr Analyst, Wound and Kris Finn, Sr Analyst, Wound, please click the button below.

Csaba Dózsa, habil PhD MSc, Health Economist, discusses his model for cost-effectiveness in the prevention and treatment of pressure injuries in an interview with SmartTRAK.

In this interview, Prof. Dózsa unveils his groundbreaking pressure injury (PI) prevention costing model. With a 20-year background in health economics, he embarked on this journey from Hungary's National Health Insurance Fund. His expertise shaped the German DRG point system locally and steered home care development. Establishing Med-Econ Ltd., he delved into diverse health economic studies, culminating in a sophisticated, non-linear model for PI prevention costs.

The model's complexity stems from recognizing intricate healthcare inputs and outcomes. It calculates annual PI costs across scenarios: implementing preventive care bundles with or without multi-layer dressings, and treatment-only approaches. Designed as a calculation framework, it showcases the efficacy of preventive wound care.

Among the many questions answered by Prof, Dózsa in this interview are:

• Can this model be used in any health and political environment?
• How does the use of this model affect a hospital's use of dressings?
• How would you describe the cost structure of prevention and treatment?
• Can this model and its outcome lead to systemic changes?
• How long would it take a hospital or hospital system to adapt the model to their data?
• Can this model be used equally in the case of higher-risk patients, older patients or in hospitals that see proportionally more of these patients?

The interview, conducted by Anikó Szekér, SmartTRAK Senior Analyst, Wound Care, offers insights into Prof. Dózsa's journey and his PI prevention costing model's potential. To download a complete transcript of the interview, just click the button below.

SmartTRAK was on-site at ASPN 2023 covering industry-sponsored RCT updates and data reveals, as well as new players and trends in the interventional pain space.

As the number of patients suffering from chronic pain increases, the interventional pain market continues to grow. Physicians and device developers are rising to the challenge by offering more personalized pain treatment options for an expanding list of indications. As a result, new differentiators for spinal cord stimulation (SCS) players have emerged, as well as newcomers in the peripheral nerve stimulation (PNS) market. Beyond neuromodulation, minimally-invasive surgical (MIS) spine procedures, sacroiliac (SI) joint fusion and regenerative medicine products also provide innovative solutions for chronic pain management. In this interesting article, SmartTRAK highlights the newest data, innovation and market developments at the American Society of Pain and Neuroscience (ASPN) 2023 Annual Meeting held in Miami, FL.

Among the many topics discussed in comprehensive detail in this article, which can be downloaded here, are:

• SCS Sees Cutthroat Competition
  • MRI Compatibility and Closed-Loop SCS
  • Painful Diabetic Neuropathy (PDN)
  • Artificial Intelligence, Programming Solutions and Remote Monitoring
• Expanding Horizons in PNS
  • Types of Peripheral Nerve Stimulation
  • Outcomes, Comfort and Wearability for Externally-powered Devices
  • Injectrode Technology
• What’s New in MIS Spine and SI Joint Fusion
  • Leveraging Enabling Technology for Pain Procedures
  • Innovations in MIS Spine and SI Joint Instrumentation
• Scientific Focus on Biologics and Regenerative Medicine

To identify current and future trends in interventional pain management and PNS, SmartTRAK recently surveyed 30 interventional pain physicians, including 18 who perform PNS, to get an inside view of procedure trends, what treatments and devices they use and who they see as future winners in the chronic pain space. To purchase the results of this comprehensive survey, see SmartTRAK’s Trends in Interventional Pain Management and PNS.

To download a complimentary copy of the complete "ASPN 2023: Advancements in Interventional Pain Treatment" article, just click the button below.

At the 2023 Annual Meeting in monumental Washington DC, the Biologic Association and the American Society of Orthopaedic Surgeons (AAOS) teamed up with American Orthopaedic Society for Sports Medicine (AOSSM) to spotlight the growing interest in and latest advancements of biologics in musculoskeletal medicine. Taking center stage and garnering attention was the idea of “biological healing” and the use of biologics in various conditions and at different points of a continuum of care.

Not surprisingly, the Biological Association focused more on autologous therapies, cell culturing and the next generation of biologics, while the AOSSM meeting explored the current use and growing trends of traditional orthobiologics in orthopedic applications. This article, which is downloadable here, is part one in a two-part series highlighting key takeaways from the Biologic Association meeting, including:

• Biologic Association Key Takeaways
• Rules of Engagement: Regulations and Needed Standards
  • “Same Surgical Procedure Exception” Guidance
  •  Standards for Autologous Orthobiologics
  • Driving Better Patient Outcomes
• Current Use of Autologous Therapies and Next Generation of Biologics
  • Current Practice
  • Next Generation of Biologics
• Notable Investigative Technologies

Although several biologics seem promising to treat musculoskeletal conditions, there is still an uphill battle for widespread use. Current challenges include ...

To download "Biologics in Musculoskeletal Medicine," Part One of the series of articles by Kimberly French, SmartTRAK's GM, Orthobiologics and Regenerative Medicine, just click the button below. Look for Part Two in this series, which will cover key takeaways from AOSSM, highlighting the current use of Orthobiologics and growing trends, in the coming weeks.

In a joint interview with Eugene Malinskiy, founder and CEO of Lazurite, and orthopedic surgeon Dr James Voos, we discuss the world’s first wireless surgical camera, the Lazurite ArthroFree camera.

Eugene Malinskiy, the founder and CEO of Lazurite, and orthopedic surgeon Dr. James Voos discuss the technological and clinical benefits of the new ArthroFree camera, the world’s first fully wireless surgical camera, with Andy Knapik, SmartTRAK's Senior Analyst, Soft Tissue & Arthroscopic Technologies.

To learn more about Lazurite and the ArthroFree System, click the following video to watch the interview (27:05 min).  For more details, interview topics by timecode are provided below. To download a complete transcript of the interview, click here.

Interview Topics By Timecode

1:25 Background of Lazurite and the ArthroFree camera.

7:05 Surgeon impressions of the ArthroFree camera.

10:10 Camera integration, image quality, battery life, ergonomics.

16:05 How the camera connects to the monitor and image capture.

19:22 How do facilities react to purchasing the ArthroFree.

22:05 Uses of the ArthroFree camera.

To download the complete transcript of the interview with Eugene Malinskiy, the founder and CEO of Lazurite, and orthopedic surgeon Dr. James Voos, just click the button below.

SmartTRAK constantly monitors the worldwide MedTech industry, sifting through the noise to present to our subscribers the most relevant international news, trends, new products, patents, financial data and competitor developments in the global Life Sciences industry. Contact Us if you'd like to learn how to receive these expert insights daily. Our users think it's the perfect way to start their day.

The following is just a small sampling of recent Neurovascular market updates from around the world compiled, reviewed and posted daily by our SmartTRAK analysts.

New Products:

• ZOOM* - Imperative Care* 
  

  Imperative Care announced the completion of first cases using the recently FDA-cleared Zoom 88 Support catheter. One of the cases was an AIS patient with a tandem occlusion treated at Erlanger Health System in Chattanooga, TN. SmartTRAK reported FDA clearance of the device on Jun 15.

• MicroPort*

   MicroPort NeuroTech announced in May 2023 that it has completed the first clinical implantation of its NUMEN Detachable Embolization Coil for neurovascular aneurysm treatment in both the UK and Ireland.

• EOSolutions Launches Dr. Banner BGC

   EOSolutions announced the full commercial launch of its Dr. Banner, Balloon Guide Catheter (BGC), developed in collaboration with InNeuroCo. According to the Company, the BGC features a 0.091 ID, proximal stability, distal trackability and a compliant polyurethane balloon.

Patents:

• phenox*
  

  phenox GmbH’s US Patent Application “Insertion System For Implants For Treatment Of Bifurcation Aneurysms” was published disclosing a Y-shaped tubular implant and Y-shaped insertion catheter for bifurcation aneurysm treatment. 20230233347

• Aspiration Catheter with an Adjustable Tip

  The Univ of Toledo’s US Patent Application “Aspiration Catheter With An Adjustable Tip For The Intracranial Circulation” was published disclosing a neurovascular aspiration catheter with an adjustable tip controlled by pull wires. 20230233221

  

The Centers for Medicare and Medicaid Services (CMS) projects Medicare home health spending in the US will grow at an 8-year (2023-2031) CAGR of +8.6% compared to +7.4% for hospital expenditures. These projections help validate that healthcare services are shifting to the home care setting. The migration is driven by efforts to reduce costs, improve access and enhance the quality of care. Policymakers continue to manipulate reimbursement formulas to incentivize change. CMS recently released the CY 2024 Home Health Prospective Payment System (PPS) Proposed Rule that includes reimbursement policy revisions that could potentially increase the utilization of disposable negative pressure wound therapy (dNPWT) in the home health setting. This free downloadable article highlights:

• The Trajectory of dNPWT,
• Historical Challenges Associated with the Uptake in the Home Setting
• Incremental Policy Efforts Designed to Mitigate Those Challenges
• Billing Complexity Stalling Growth
• Incremental Changes Show Progress
• Impact of Proposed Policy Changes. 

With the establishment of a separate payment for the dNPWT and the relatively simpler billing processes, the proposed CMS changes are a net positive for manufacturers treating wounds in the home health setting. However, given the growing competition ...

To download the complete "CMS Proposed Rule Incentivizes Home Use of Disposable NPWT" perspective article by Terry Hayslett, SmartTRAK Senior Analyst, Advanced Wound Care, just click the button below.

• Complete Q123 Trauma Market Overview
• SmartTRAK's Expert Market Analysis and Insights
• All Trauma Companies' News, Revenues, Data, Charts and Market Shares
• IM Nailing Closes the Quarter on High with Solid Returns
• New Regulatory Clearances Propel the Pediatric Trauma Segment:
  • OrthoPediatrics
  • NuVasive Specialized Orthopedics, Inc.
  • Wishbone Medical
• Q123 Trauma Regulatory Highlights

During Q1, the Pediatric Trauma segment experienced a notable surge in regulatory clearances, indicating forthcoming product launches aimed at bolstering the segment's growth. These approvals signal  ...

Read the entire Q123 Trauma Market Recap, including SmartTRAK's expert analysis, news, data, charts, revenues and shares*

*These links and the complete unedited article can only be viewed by SmartTRAK subscribers to this module. For more information on SmartTRAK, including how to receive a demo and subscribe, please click the button below.

SmartTRAK’s survey of interventional pain physicians reveals valuable insights into current and future trends in interventional pain management and peripheral nerve stimulation (PNS)

SmartTRAK recently conducted a survey of 30 interventional pain physicians, including 18 doctors who perform PNS, to gain insight into the current state of interventional pain management and identify future trends in the field. This includes physician use of SCS, DRG Stimulation, short- and long-term PNS, RFA, TDD, Regenerative Medicine injections and MIS spine procedures, with an emphasis on PNS companies and technologies.

This comprehensive study sheds light on procedure trends, preferred treatment approaches, physicians' perspectives on PNS and more!

Key questions include:

• What interventional pain procedures are expected to grow the most in the next 12-24 months?
• What minimally invasive spine procedures do physicians think will increase the most in the next few years?
• What are expected procedure volumes for Regenerative Medicine injections?
• What are the most preferred treatment approaches for different chronic pain conditions?
• What are physicians' impressions of the different PNS technologies/brands?
• What are the top targets for PNS and what's driving and limiting physician adoption of PNS?
• What technology improvements do physicians want to see in PNS devices?

Click the button below if you are interested in purchasing SmartTRAK’s Interventional Pain Management and Peripheral Nerve Stimulation Survey. Be The Expert with the latest insights and trends in the field and equip yourself with valuable knowledge. Click Now!

Among the many topics covered in detail in SmartTRAK's comprehensive Q123 Spine Market Recap* are:

• Complete Q123 Spine Market Overview
• SmartTRAK's Expert Market Analysis and Insights
• All Spine Companies' News, Revenues, Data, Charts and Market Shares
• Top Players' Performance
  •  JNJ/DePuy Synthes
  • Globus 
  • NuVasive 
  • Stryker
• Q123 Spine Trends
  • M&A Activity
  • New Products
  • Reimbursement Dynamics
• Regulatory Highlights
• Europe Regulatory Updates
• Clinical Study Progress

Orthofix and SeaSpine announced the completion of its merger in Q123 in which SeaSpine became a wholly owned subsidiary of Orthofix. In a recent note, Canaccord Genuity highlighted SeaSpine, 7D Surgical and Simplify as the most notable of the recent spine acquisitions. SmartTRAK agrees and notes that ...

Read the entire Q123 Spine Market Recap, including SmartTRAK's expert analysis, news, data, charts, revenues and shares*

*These links and the complete unedited article can only be viewed by SmartTRAK subscribers to this module. For more information on SmartTRAK, including how to receive a demo and subscribe, please click the button below.

Discover how Europe is transforming into a hotbed of innovation for chronic wound care through the breakthrough technology of cold plasma therapy. As the global focus on chronic wounds intensifies, European markets are witnessing a surge in new technologies that offer promising solutions. From smaller, portable devices to collaborative research efforts, this article highlights the rise of cold plasma therapy and its potential to revolutionize wound care. Download the article to further explore these, and other, key points:

• Europe's lower revenue levels for advanced wound therapies compared to the US present an opportunity for new technologies to thrive.
• Cold plasma therapy, utilizing low-temperature atmospheric pressure plasmas, demonstrates impressive benefits in treating chronic wounds, including bacterial inactivation and enhanced healing.
• Recent advancements have led to the development of smaller and more portable cold plasma devices, expanding treatment options beyond hospitals to ambulatory settings and even patients' homes.
• Swiss company ActivCell Group Ag, German companies neoplas med GmbH and Plasmacure BV and Dutch company Terraplasma Medical GmbH are among the pioneering companies offering innovative cold plasma devices.
• The future of cold plasma therapy depends on the willingness of companies to collaborate, navigate regulatory challenges, and establish a distinct market presence.
• While European advancements in cold plasma therapy are promising, the highly competitive US market remains a long-term goal for most companies, necessitating FDA approval and strategic partnerships.
• The rapid growth of topical oxygen therapy in the US, driven by initiatives like the Veterans Association and state-level Medicaid approvals, could potentially outpace European progress once FDA approval is obtained.

The full article delves into the transformative potential of cold plasma therapy in chronic wound care. Explore the advancements, collaborations and challenges that shape Europe's emerging market and its race against the US in revolutionizing wound treatment. Just click the button below to download the complete "EWMA 2023 - Cold Plasma Poised for Growth in Europe" article by Kris Flinn, SmartTRAK Senior Analyst - Wound.

Soft Tissue Fixation Rebounds in Q123 To Start the Year In a Positive Direction

In Q1, the STF market experienced notable growth, primarily driven by several factors, including an increase in elective procedures, a decrease in the effects of supply chain issues and increased growth over a sluggish Q122. Overall, these factors collectively propelled the STF market to exhibit robust growth during the first quarter.

Among the many topics covered in detail inSmartTRAK's comprehensiveQ123 Soft Tissue Fixation Market Recap* are:

• Complete Q123 Soft Tissue Fixation Market Overview
• SmartTRAK's Expert Market Analysis and Insights
• All STF Companies' News, Revenues, Data, Charts and Market Shares
• Headwinds and Tailwinds
• Top Competitor Results & Highlights
• Q123 Clinical/Regulatory Highlights

In the first quarter of 2023, the orthopedic ambulatory surgical center (ASC) market in the US experienced positive developments. The market witnessed significant growth in personnel, contracts and portfolio expansion within Sports Medicine companies. In their Q1 earnings call, Zimmer Biomet* COO Ivan Tornos commented that ...

In addition to product innovation and increasing adoption, the Spine Enabling Technology market is rapidly evolving due to mergers and acquisitions.

The Q123 WW Spine Enabling Tech Market was up +12.6% YoY, according to SmartTRAK Financial Dashboard. Medtronic (MDT) remained the market leader with 54.9% share, followed by Globus Medical (GMED) and other enabling tech competitors like Brainlab and Stryker (SYK). For detailed Q123 revenues and shares by company in the US, EU and ROW, see SmartTRAK Spine Enabling Tech Financial Dashboard*.

Among the many topics covered in detail in SmartTRAK's comprehensive Q123 US Spine Enabling Technology Market Recap* are:

• Complete Q123 Spine Enabling Tech Market Overview
• SmartTRAK's Expert Market Analysis and Insights
• All Companies' News, Revenues, Data, Charts and Market Shares
• Mergers and Acquisitions Changing the Spine Enabling Technology Landscape
• New Spine Robots on the Horizon
• Milestones in Augmented Reality
• Q123 Regulatory Highlights

In February 2023, GMED announced it entered into a definitive agreement to combine in an all-stock transaction with NuVasive (NUVA). The transaction is expected to close mid-2023 subject to shareholder and regulatory agency approvals, which will make the combined company the ...

Read the entire Q123 Spine Enabling Tech Market Recap, including SmartTRAK's expert analysis, news, data, charts, revenues and shares*

*These links and the complete unedited article can only be viewed by SmartTRAK subscribers to this module. For more information on SmartTRAK, including how to receive a demo and subscribe, please click the button below.

Among the many topics covered in detail in SmartTRAK's comprehensive Q123 US Orthobio Market Recap* are:

• Complete Q123 Orthobio Market Overview
• SmartTRAK's Expert Market Analysis and Insights
• All Orthobio Companies' News, Revenues, Data, Charts and Market Shares
• US Bone Replacement – Springing Back Into Light
  • Growth Factors/Peptides
  • DBM and Synthetics
• US Cartilage Replacement –The Light Continues To Shine Bright
  • Cellular Grafts
  • Osteochondral Grafts
• US Soft Tissue Replacement – Sunny Days Continue
  • Soft Tissue Patches
  • Tendon Allografts
• US Meniscus Replacement – Sun is Shining Back on The Market

Despite continued healthcare staffing shortages and economic uncertainties, the US Bone Replacement experienced high single-digit percentage growth in Q123 as it benefited from increased utilization, especially in ...

Read the entire Q123 US Orthobio Market Recap, including SmartTRAK's expert analysis, news, data, charts, company revenues and shares*

*These links and the complete unedited article can only be viewed by SmartTRAK subscribers to this module. For more information on SmartTRAK, including how to receive a demo and subscribe, please click the button below.

This SAWC Spring 2023 perspective article extensively covers a wide range of topics pertaining to skin substitutes and Cellular and Tissue-based Products (CTPs), offering in-depth insights and analysis, and highlights a multitude of areas for discussion. Some of the key topics explored in this article include:

• CAMP Companies and Products Dominate
  • Spring SAWC was dominated by companies showcasing their CAMPs, with nearly 30 companies exhibiting this year. The market is currently led by ...
    
• Reimbursement: It’s Complicated
  • Skin substitute utilization is heavily influenced by reimbursement and setting of care. The physician office currently captures the largest share of the skin substitutes market. This is primarily driven by ...
    
• Emerging Sites of Care
  • In its Site of Care module, SmartTRAK currently tracks the use of CTP or CAMP products in the surgical suite, HOPD, physician office, VA Health system and burn center. In discussions at SAWC, SmartTRAK learned ...
• Future Growth
  • Despite reimbursement hurdles, SmartTRAK projects strong growth for this segment in the coming years, primarily due to ...
    

To download and read the complete "SAWC Spring 2023: Spotlight on the Skin Substitute Market" market perspective article by Susan Paquette, SmartTRAK's VP & General Manager, Wound, just click the button below.

Continued strength in ortho robotics placements and a crowd of new product launches in Q123 set the stage for growth in the remainder of the year.

Among the many topics covered in detail in SmartTRAK's comprehensive Q123 Ortho Enabling Tech Market Recap* are:

• Complete Q123 Otho Enabling Tech Market Overview
• SmartTRAK's Expert Market Analysis and Insights
• All US Ortho Enabling Tech Companies' News, Revenues, Data, Charts and Market Shares
• Robust Q123 Robotics Performances by Company
  
  • Stryker
  • Zimmer Biomet
  • Smith+Nephew
  • JNJ/Depuy Synthes
• New Product Introductions
  
  • Robotics and Ecosystem Launches
  • Navigation and Planning Innovations
• SmartTRAK's Selected Highlights from Q123 Conferences
  
  • JP Morgan 41st Annual Healthcare Conference
  • Canaccord Genuity 2023 Musculoskeletal Conference
  • AAOS 2023 Annual Meeting

In an International Society for Technology in Arthroplasty (ISTA) presentation at the American Academy of Orthopaedic Surgeons 2023 (AAOS 2023) Annual Meeting, President, Digital, Robotics and Enabling Technology at SYK Robert Cohen discussed innovations including a fully connected operating room for a common user experience with planning and mixed-reality guidance combined with robotics and data transfer capabilities. Enabling technology continues to see adoption and integration in orthopedics and with it, the introduction of ...

Read the entire Q123 Ortho Enabling Tech Market Recap, including SmartTRAK's expert analysis, news, data, charts, company revenues and shares*

*These links and the complete unedited article can only be viewed by SmartTRAK subscribers to this module. For more information on SmartTRAK, including how to receive a demo and subscribe, please click the button below.

Biologics had a whopping quarter, Advanced Dressings saw strong gains and External Devices continue to show minimal gains due to traditional NPWT holding down the segment.

The global AWC market is split geographically, with the US accounting for just over half, followed by Europe and then ROW, due to the US using higher technology products and their allowed reimbursement. SmartTRAK has noted shifts in market share, largely driven by currency movements. In Q123, there was less of an impact. From Q221 to Q123, the US went from 52.6% share to 53.1%, Europe from 27.9% to 28.6% and ROW from 19.5% to 18.2%.

Among the many topics covered in detail in SmartTRAK's comprehensive Q123 Advanced Wound Care Market Recap* are:

• Complete Q123 Advanced Wound Care Market Overview
• SmartTRAK's Expert Market Analysis and Insights
• All AWC Companies' News, Revenues, Data, Charts and Market Shares
• WW Advanced Dressings: Acceleration of Continued Solid Growth
• Biologics: An Impressive Quarter
  
  • Skin Substitutes/CTPs
  • Topical Delivery/Drug
  • Collagen/Active Dressings
• External Devices: Single-use NPWT and Topical Oxygen Therapy Drive Growth
• Growth Analysis – Currency Having a Less Strong Impact
  • Growth Details for Key Companies in Q123
• Other Notable Q123 AWC Events

3M remained the global revenue leader in the Q123 WW AWC market, with Smith+Nephew (SNN) is in second place and Mölnlycke rounding out the top three,  with revenues of ...

Read the entire Q123 AWC Market Recap, including SmartTRAK's expert analysis, news, data, charts, company revenues and shares*

*These links and the complete unedited article can only be viewed by SmartTRAK subscribers to this module. For more information on SmartTRAK, including how to receive a demo and subscribe, please click the button below.

New SaaS technology offering delivers competitive advantage in rapidly changing Ambulatory Surgery Center market.

SmartTRAK, the leading global Medtech business and market software intelligence solution in the Orthopedics, Wound Care, Regenerative Medicine and Neuro Therapy markets, is pleased to announce the release of ASC Insights, the industry’s first-ever commercially available platform-based solution for the growing Ambulatory Surgery Center (ASC) market. ASC Insights provides real-time insights and rich data to help clients better understand market trends and accelerate commercial growth strategies.

In recent years, the Orthopedic ASC market, valued at over $10 billion, has undergone a significant transition as surgeries increasingly shift from traditional inpatient settings to outpatient ASCs. This shift necessitates that Medtech companies explore new ways to stay informed about myriad data sources and market shifts to drive their commercial growth strategies.

The ASC Insights offering is an extension of the SmartTRAK platform, encompassing comprehensive market analyses and proprietary qualitative insights on trends, as well as readily extractable quantitative metrics. Alternatively, enterprise customers can seamlessly integrate these metrics into their business intelligence platforms. Subscribers to SmartTRAK ASC Insights gain access to a historical news archive, recaps of changes in key facility ownership and information on technologies and reimbursement. Furthermore, customers receive valuable Daily Updates, ensuring up-to-date and timely coverage of noteworthy ASC industry developments. They also enjoy on-demand, direct access to SmartTRAK expert analysts.

New products and technologies in Shoulder Replacement and the Extremities Fixation Segments planted the seeds for sequential growth in the Q123 Extremities Market

The US Extremities Market grew 7.8% in Q123 with new products and continued recovery of elective procedures encouraging growth despite concerns about a looming recession. While headwinds such as supply chain constraints, economic challenges and staffing shortages could darken the forecast, SmartTRAK expects the Extremities Market to weather these issues and continue to experience strong growth through 2023.

Among the many topics covered in detail in SmartTRAK's comprehensive Q123 Extremities Market Recap* are:

• Complete Q123 Extremities Market Overview
• SmartTRAK's Expert Market Analysis and Insights
• All Company News, Revenues, Data, Charts and Shares
• New Products and Technologies That are Planting the Seeds for Growth in Shoulders
• Extremities Fixation Closes the Quarter on High with Solid Returns
• Q123 Regulatory Highlights

Both US Extremities Fixation subsegments, Upper Extremities Fixation and Foot Ankle Fixation, ended the first quarter of 2023 with ...

Read the entire Q123 Extremities Market Recap, including SmartTRAK's expert analysis, news, data, charts, company revenues and shares*

*These links and the complete unedited article can only be viewed by SmartTRAK subscribers to this module. For more information on SmartTRAK, including how to receive a demo and subscribe, please click the button below.

The success or failure of medical technology often hinges on dynamics occurring within healthcare policy and reimbursement. In this article, SmartTRAK highlights policy and reimbursement themes from SAWC Spring 2023

SAWC Spring 2023 welcomed clinicians, researchers and industry to Washington, DC, to share knowledge and network on the latest developments in advanced wound care. While the attention centered on advances in disease management and technological innovation, SmartTRAK noted compelling discussions involving healthcare policy and reimbursement that may have been missed by some industry participants.

In this article, which can be downloaded here, SmartTRAK explores coverage and payment dynamics surrounding the following topics:

• Artificial Intelligence: Implications for Advanced Wound Care
  • Artificial Intelligence (AI) is the hot topic of the day. Companies seek to capitalize on it, governments want to regulate it, some workers fear it ...
    
• Medicare Advantage: Growing Concerns About Claims Denials
  • Medicare Advantage plans are under fire for reportedly restricting access to medically necessary care ...
    
• Topical Oxygen Therapy: Reconsidering Local MAC Coverage Policy
  • In 2017, industry stakeholders requested that CMS remove the non-coverage of topical oxygen therapies (TOT) from the National Coverage Determination (NCD) Manual ...
    

Artificial Intelligence (AI) is the hot topic of the day. Companies seek to capitalize on it, governments want to regulate it and some workers fear it. Given the attention, it is fitting that sessions touching on AI bookended SAWC Spring 2023. Daniel Kraft, MD, opened the keynote address with captivating slides on how medicine is positioned within the fourth industrial revolution, where robotics, big data and AI are transforming care and leading to ...

To download and read the complete "Underlying Dynamics in Healthcare Policy and Reimbursement" by Terry Hayslett, Senior Analyst, Advanced Wound Care, just click the button below.

Among the many topics covered in detail in SmartTRAK's comprehensive Q123 Total Joints Market Recap* are:

• Complete Q123 Total Joints Market Overview
• SmartTRAK's Expert Market Analysis and Insights
• All Company News, Revenues, Data, Charts and Shares
• Technologies and Procedure Recovery Elevating Hip Growth
• The Ongoing March Towards Cementless Knees
• Deals and Financing Highlights
• Q123 Regulatory Highlights

Will this momentum continue throughout 2023? SmartTRAK believes underlying demand for hip and knee replacement surgery will ...